<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ocular side effects of systemically administered chemotherapy</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ocular side effects of systemically administered chemotherapy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Ocular side effects of systemically administered chemotherapy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Catherine Y Liu, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jasmine H Francis, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David H Abramson, MD, FACS</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul J Hesketh, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Matthew F Gardiner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2155561388"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Molecularly targeted agents have emerged as an important component of systemic therapy for a wide range of cancer types. Most of these agents work through mechanisms that are markedly different from conventional cytotoxic chemotherapy, interfering with cellular signaling and angiogenesis pathways that are needed for tumor growth. Many of these agents are associated with distinct adverse effect profiles, several of which affect the eye. Although relatively uncommon, ocular side effects from targeted agents can be severe, disabling, and irreversible. While some ocular side effects can be managed symptomatically while chemotherapy is continued, others can be vision threatening and warrant immediate discontinuation of the drug.</p><p>The ocular side effects of intra-arterial chemotherapy administration (including chemotherapy administered into the ophthalmic artery for retinoblastoma) are beyond the scope of this topic review. (See  <a class="medical medical_review" href="/d/html/107561.html" rel="external">"Retinoblastoma: Treatment and outcome", section on 'Local chemotherapy'</a>.)</p><p class="headingAnchor" id="H1413662672"><span class="h1">OVERVIEW OF THE APPROACH TO THE PATIENT WITH OCULAR SYMPTOMS</span><span class="headingEndMark"> — </span>When a patient receiving chemotherapy presents with a specific ocular sign or symptom, it is important to delineate whether the complaint is due to the malignancy itself, an associated effect (eg, a paraneoplastic syndrome), or the anticancer treatment.</p><p>In general, paraneoplastic visual syndromes are rare; they include cancer-associated retinopathy, melanoma-associated retinopathy, and paraneoplastic optic neuropathy (optic neuritis). (See  <a class="medical medical_review" href="/d/html/15837.html" rel="external">"Paraneoplastic visual syndromes"</a>.)</p><p class="headingAnchor" id="H3166578896"><span class="h2">Differentiating metastasis from drug toxicity</span><span class="headingEndMark"> — </span>The most common intraocular malignancy is metastatic disease, which most commonly involves the uveal tract. The uvea consists of the iris and ciliary body anteriorly, and the choroid posteriorly  (<a class="graphic graphic_figure graphicRef57690" href="/d/graphic/57690.html" rel="external">figure 1</a>).</p><p>Choroidal metastases typically appear as elevated amelanotic choroidal lesions with an overlying patchy disturbance of the retinal pigment epithelium  (<a class="graphic graphic_picture graphicRef122412" href="/d/graphic/122412.html" rel="external">picture 1</a>). They are often accompanied by an overlying serous retinal detachment that appears out of proportion to the lesion itself. Symptoms can depend on the location of the metastasis: a peripherally located tumor with minimal serous fluid can be asymptomatic, while lesions or subretinal fluid involving the macula can result in symptoms that include photopsia (a subjective sensation of flashing lights, sparks, or colors), metamorphopsia (a condition where objects appear distorted), floaters, blurry vision, difficulty focusing, and dyschromatopsia (abnormality in the ability to perceive colors). While some of these symptoms can be shared with the effects of drug toxicity, a dilated fundus examination, often supplemented with ocular ultrasound and optical coherence tomography, will usually distinguish choroidal metastases from drug-induced retinopathy.</p><p>There can also be metastases to the orbit or optic nerve, which can cause optic disc swelling. Disc swelling can also be seen secondary to metastases to the brain causing papilledema. Cross-sectional imaging of the head can help with diagnosis in these cases. (See  <a class="medical medical_review" href="/d/html/5241.html" rel="external">"Overview and differential diagnosis of papilledema"</a>.)</p><p>Metastases to the retina can cause retinal inflammation and intraretinal hemorrhages, while metastases to the vitreous accumulate leucocytes in the vitreous humor. This can appear as vitritis (inflammation in the vitreous  (<a class="graphic graphic_figure graphicRef57690" href="/d/graphic/57690.html" rel="external">figure 1</a>)). A dilated fundus examination and possible biopsy of the vitreous can help with differentiation between true vitritis and metastases. (See <a class="local">'Uveitis and ocular inflammation'</a> below.)</p><p class="headingAnchor" id="H3104827064"><span class="h2">Localizing the compartment affected by ocular toxicity</span><span class="headingEndMark"> — </span>Different compartments of the eye  (<a class="graphic graphic_figure graphicRef57690" href="/d/graphic/57690.html" rel="external">figure 1</a>) are preferentially affected by different agents. Presenting signs and symptoms can help localize which compartment of the eye (ie, the cornea, uvea [choroid, ciliary body, and iris], periocular and orbital tissue, retina, and/or optic nerve) is affected:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cornea and anterior segment</strong> – Cornea damage from dry eye triggers reflexive tearing; burning; gritty, sandy, or foreign body sensation; sensitivity to light; and blurred vision. The conjunctiva may be injected (diffusely red). Drug-induced conjunctivitis may present with a pinkish hue, chemosis (a collection of serous fluid within the conjunctiva that reflects conjunctival irritation), and a discharge from the eyes. Blepharitis is characterized by inflammation of the base of the eyelashes (anterior blepharitis  (<a class="graphic graphic_picture graphicRef64540" href="/d/graphic/64540.html" rel="external">picture 2</a>)) or the inner portion of the eyelid at the level of the meibomian glands (posterior blepharitis  (<a class="graphic graphic_picture graphicRef61924" href="/d/graphic/61924.html" rel="external">picture 3</a>)). Most of these patients can be managed symptomatically while chemotherapy is continued. (See <a class="local">'Cornea and anterior segment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uvea (choroid, ciliary body, and iris)</strong> – Symptoms of inflammation of the uveal structures (uveitis) include blurred vision; dark, floating spots in the vision (floaters); eye pain; redness in the eye; sensitivity to light (photophobia); and vision loss. Inflammation of the uveal tract can present as anterior uveitis (involving the anterior ocular compartment  (<a class="graphic graphic_figure graphicRef57690" href="/d/graphic/57690.html" rel="external">figure 1</a>)), intermediate uveitis, posterior uveitis, or panuveitis (involving all ocular compartments).</p><p></p><p class="bulletIndent1">Patients suspected of having drug-induced uveitis need urgent referral to ophthalmology for examination. (See <a class="local">'Uveitis and ocular inflammation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Periocular and orbital tissue</strong> – Periocular tissue changes may include abnormalities of the eyelashes, scarring and outward turning of the lower lid (ectropion  (<a class="graphic graphic_picture graphicRef72737" href="/d/graphic/72737.html" rel="external">picture 4</a>)), chalazia (large, painful, inflamed, erythematous and nodular lesions that appear over days on the upper or lower lids due to a lipogranulomatous reaction  (<a class="graphic graphic_picture graphicRef80892" href="/d/graphic/80892.html" rel="external">picture 5</a>)), excess tearing with or without nasolacrimal duct obstruction, and periorbital edema. These conditions are generally treated symptomatically with continued drug treatment, but sometimes ophthalmologic referral and drug discontinuation are indicated. (See <a class="local">'Orbit and periorbital tissue'</a> below.)</p><p></p><p class="bulletIndent1">By contrast, orbital inflammation is associated with pain with eye movement, orbital congestion (conjunctival injection and chemosis), proptosis of the eye, exposure keratopathy, ophthalmoplegia and diplopia, potential optic neuropathy, and blindness. This is an emergency, and immediate drug discontinuation and prompt evaluation with a specialist are recommended. (See <a class="local">'Orbital inflammation'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retina and/or optic nerve</strong> – The development of<strong> </strong>visual loss with or without ocular pain should always raise the possibility of damage to the retina and/or optic nerve. These patients warrant withholding of the suspected drug and urgent referral to an ophthalmologist. (See <a class="local">'Retina'</a> below.)</p><p></p><p class="headingAnchor" id="H1508940711"><span class="h2">Grading the severity of ocular/visual side effects</span><span class="headingEndMark"> — </span>The Common Terminology Criteria Adverse Events reporting system of the National Cancer Institute (NCI-CTCAE) includes grading tables for the severity of several eye disorders, including blurred vision, cataract, conjunctivitis, corneal ulcer, dry eye, extraocular muscle paresis, eye pain, eyelid function disorder, flashing lights, floaters, glaucoma, keratitis, night blindness, optic nerve disorder, papilledema, photophobia, retinal detachment, retinal tear, retinal vascular disorder, retinopathy, scleral disorder, uveitis, vitreous hemorrhage, watery eyes, and other toxicities [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H27977894"><span class="h1">CLINICAL MANIFESTATIONS OF DRUG TOXICITY AND OVERVIEW OF MANAGEMENT</span></p><p class="headingAnchor" id="H27977900"><span class="h2">Cornea and anterior segment</span><span class="headingEndMark"> — </span>Several chemotherapy agents can affect the cornea, causing dry eye, meibomian gland dysfunction and blepharitis, nonhealing epithelium and corneal melt, corneal deposits, conjunctivitis, conjunctival hemorrhage, and cataracts.</p><p class="headingAnchor" id="H751782700"><span class="h3">Dry eyes</span><span class="headingEndMark"> — </span>Corneal defects associated with dry eye trigger reflexive tearing; burning; gritty, sandy, or foreign body sensation; and sensitivity to light. The blurred vision associated with dry eyes tends to be variable, but blurriness often improves with blink.</p><p>There is no single definitive test or consensus of criteria to diagnose dry eye [<a href="#rid2">2</a>]. Given the lack of clinically measurable signs and available diagnostic testing, dry eye is diagnosed primarily on the basis of patient symptoms and supporting findings on the physical examination (which may include conjunctival injection, the paradoxical finding of excess tearing, and a reduced blink rate). (See  <a class="medical medical_review" href="/d/html/6894.html" rel="external">"Dry eye disease", section on 'Diagnosis'</a>.)</p><p>Lubrication with <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> can help symptoms. Artificial tears generally include cellulose to maintain viscosity, a spreading agent, such as polyethylene glycol or polyvinyl alcohol, to prevent evaporation, and a preservative to prevent contamination. Available without a prescription, artificial tears come in liquid, gel, and ointment form. (See  <a class="medical medical_review" href="/d/html/6894.html" rel="external">"Dry eye disease", section on 'Artificial tears'</a>.)</p><p>Severe cases can sometimes be improved with a short trial of topical corticosteroids or with topical (ophthalmic) <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>. (See  <a class="medical medical_review" href="/d/html/6894.html" rel="external">"Dry eye disease", section on 'Topical cyclosporine'</a>.)</p><p><a class="drug drug_general" data-topicid="109082" href="/d/drug information/109082.html" rel="external">Lifitegrast</a> is an alternative agent that can be used as well. (See  <a class="medical medical_review" href="/d/html/6894.html" rel="external">"Dry eye disease", section on 'Topical lifitegrast'</a>.)</p><p>For patients with excess tearing caused by dry eye, punctal occlusion using temporary or permanent punctal plugs can help diminish tear outflow. These can be placed by a general ophthalmologist or a cornea specialist. (See  <a class="medical medical_review" href="/d/html/112281.html" rel="external">"Treatment of moderate to severe dry eye in Sjögren’s disease", section on 'Punctal occlusion'</a>.)</p><p>Topical <a class="drug drug_general" data-topicid="10047" href="/d/drug information/10047.html" rel="external">vitamin A</a> (retinyl palmitate) can also help, especially in cases of vitamin A deficiency [<a href="#rid3">3-5</a>]. For severe cases, referral to a cornea specialist can be beneficial. Although dry eye symptoms can be quite uncomfortable, it is generally not vision threatening.</p><p class="headingAnchor" id="H795105869"><span class="h3">Blepharitis and meibomian gland dysfunction</span><span class="headingEndMark"> — </span>Blepharitis is a chronic eye condition characterized by inflammation of the eyelids. Anterior blepharitis is characterized by inflammation at the base of the eyelashes  (<a class="graphic graphic_picture graphicRef64540" href="/d/graphic/64540.html" rel="external">picture 2</a>). Posterior blepharitis is characterized by inflammation of the inner portion of the eyelid at the level of the meibomian glands  (<a class="graphic graphic_picture graphicRef61924" href="/d/graphic/61924.html" rel="external">picture 3</a>) (eg, meibomian gland dysfunction) [<a href="#rid6">6</a>]. Meibomian glands are modified sebaceous glands located within the tarsal plates of the eyelids. These glands are responsible for secretion of the oily layer of the tear film. This oily layer is critical for normal lubrication of the eye; it prevents tear evaporation, reduces the surface tension of the tear layer, and facilitates the spread of tears over the eye [<a href="#rid7">7</a>]. (See  <a class="medical medical_review" href="/d/html/6915.html" rel="external">"Blepharitis"</a>.)</p><p>Meibomian gland dysfunction and blepharitis can cause pruritus, transient blurry vision improved with blinking, a foreign body sensation, and dry eye symptoms. Examination can show crusting of eyelids and eyelid margin inflammation; oily white plugs may be visible at the meibomian gland openings  (<a class="graphic graphic_picture graphicRef61924" href="/d/graphic/61924.html" rel="external">picture 3</a>). The two classes of agents most commonly associated with blepharitis are the epidermal growth factor receptor (EGFR) inhibitors and the proteasome inhibitor <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>. (See <a class="local">'Epidermal growth factor receptor (EGFR) inhibitor'</a> below and <a class="local">'Bortezomib and eyelid disorders'</a> below.)</p><p>Mild cases can be managed conservatively with daily lid scrubs using baby shampoo and warm water, and warm compresses. Antibiotic or combination antibiotic and steroid ointment can be used as a scrub along the lash line as well. Systemic omega-3 fatty acids can also help [<a href="#rid8">8</a>]. Significant eyelid margin inflammation can sometimes improve with systemic <a class="drug drug_general" data-topicid="9393" href="/d/drug information/9393.html" rel="external">doxycycline</a>. Referral to a cornea specialist can help with severe cases. This condition can predispose to formation of a chalazion, a chronic inflammatory lesion that develops when a meibomian tear gland of the eyelid becomes obstructed  (<a class="graphic graphic_picture graphicRef80892" href="/d/graphic/80892.html" rel="external">picture 5</a> and <a class="graphic graphic_picture graphicRef62030" href="/d/graphic/62030.html" rel="external">picture 6</a>). (See <a class="local">'Chalazia and other eyelid masses'</a> below and  <a class="medical medical_review" href="/d/html/6915.html" rel="external">"Blepharitis"</a> and  <a class="medical medical_review" href="/d/html/6898.html" rel="external">"Eyelid lesions"</a>.)</p><p class="headingAnchor" id="H2553415205"><span class="h3">Corneal epithelial defects</span><span class="headingEndMark"> — </span>Poor healing of the epithelial layer of the cornea  (<a class="graphic graphic_figure graphicRef90887" href="/d/graphic/90887.html" rel="external">figure 2</a>) has been reported frequently with EGFR inhibitors. Poor healing may lead to persistent corneal epithelial defects and erosions. (See <a class="local">'Epidermal growth factor receptor (EGFR) inhibitor'</a> below.)</p><p>The symptoms associated with nonhealing corneal epithelium are similar to those of dry eye but are more severe, especially the blurriness of vision, and burning and stinging pain [<a href="#rid9">9</a>]. In addition, nonhealing corneal epithelium can potentially increase the risks of infectious (especially bacterial) keratitis (inflammation of the cornea of the eye). Nonhealing corneal epithelium can also increase the risk of corneal ulcers  (<a class="graphic graphic_picture graphicRef75303" href="/d/graphic/75303.html" rel="external">picture 7</a> and <a class="graphic graphic_picture graphicRef55332" href="/d/graphic/55332.html" rel="external">picture 8</a>), which are vision threatening and need immediate attention. (See  <a class="medical medical_review" href="/d/html/6900.html" rel="external">"The red eye: Evaluation and management", section on 'Infectious keratitis'</a> and  <a class="medical medical_review" href="/d/html/6897.html" rel="external">"Corneal abrasions and corneal foreign bodies: Clinical manifestations and diagnosis"</a>.)</p><p>Given the problem with poor healing, symptoms may not be relieved with lubrication alone (<a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>). We suggest that patients with corneal abrasions receive topical antibiotics to prevent superinfection, rather than no treatment. Coverage with antibiotic eye drops or ointment, a bandage contact lens, and temporary tarsorrhaphy can help to prevent ulcer formation. (See  <a class="medical medical_review" href="/d/html/90922.html" rel="external">"Corneal abrasions and corneal foreign bodies: Management"</a>.)</p><p>Corneal thinning and melt are other types of epithelial defects that have been reported with EGFR inhibitors; although rare, they are potentially vision threatening, as they may lead to corneal perforation requiring corneal transplant [<a href="#rid10">10</a>]. (See <a class="local">'Epidermal growth factor receptor (EGFR) inhibitor'</a> below.)</p><p>Eye pain, change in vision, increased tearing, and light sensitivity are all possible symptoms. Sometimes a white/tan-colored round lesion can be seen on the cornea on gross observation, which can represent an ulcer. Without a slit lamp, it may be difficult to diagnose corneal thinning or melt. It generally does not have an infiltrate, as seen with corneal ulcers. On the other hand, ulcers may not be readily apparent without a slit lamp examination either if they are small. Both conditions are potentially vision threatening and should be referred if suspected. Aggressive lubrication with preservative-free <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> or ointments can be started in the interim.</p><p class="headingAnchor" id="H2931920966"><span class="h3">Corneal deposits</span><span class="headingEndMark"> — </span>Corneal deposits, including verticillata, can be associated with a variety of chemotherapy agents, including <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a>, the multikinase inhibitor <a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">vandetanib</a>, and <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. They may cause mild blurry vision and glare [<a href="#rid11">11</a>]. Symptomatic treatments with lubricants (<a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>) and topical corticosteroids may control symptoms [<a href="#rid11">11</a>]. (See <a class="local">'Tyrosine kinase inhibitors'</a> below and <a class="local">'Cytarabine and fludarabine'</a> below and <a class="local">'Tamoxifen and toremifene'</a> below.)</p><p class="headingAnchor" id="H959683386"><span class="h3">Conjunctivitis</span><span class="headingEndMark"> — </span>Drug-induced conjunctivitis typically causes a pinkish hue to the conjunctiva, chemosis (a collection of serous fluid within the substance of the conjunctiva, which is a nonspecific sign of conjunctival irritation  (<a class="graphic graphic_picture graphicRef78585" href="/d/graphic/78585.html" rel="external">picture 9</a>)) increased tearing, and a ropey discharge. Although the eye appears injected, it is not associated with eye pain, and the vision is not affected. The drugs most commonly implicated are the BRAF inhibitor <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>, and anthracyclines and related agents. (See <a class="local">'BRAF inhibitors'</a> below and <a class="local">'Anthracyclines and anthracenediones'</a> below and <a class="local">'Cytarabine and fludarabine'</a> below.)</p><p>Conjunctivitis can be caused by infectious and allergic etiologies as well. Patient history is important (ie, recent contact with someone with infectious conjunctivitis versus associated symptoms of seasonal allergies). If the diagnosis is unclear, referral to an ophthalmologist can be beneficial since a careful slit lamp examination can help to differentiate. (See  <a class="medical medical_review" href="/d/html/6907.html" rel="external">"Conjunctivitis"</a>.)</p><p>Some cases of drug-induced conjunctivitis (eg, doxorubicin-associated) resolve quickly on their own. In other cases, a short course of topical corticosteroids can be considered. (See <a class="local">'Anthracyclines and anthracenediones'</a> below.)</p><p class="headingAnchor" id="H2013176874"><span class="h3">Conjunctival hemorrhage</span><span class="headingEndMark"> — </span>Conjunctival/subconjunctival hemorrhage, as has been rarely reported with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, can appear dramatic, with a blood-red-colored eye  (<a class="graphic graphic_picture graphicRef51578" href="/d/graphic/51578.html" rel="external">picture 10</a>), but it is also painless, non-vision threatening, and usually resolves without need for treatment. (See <a class="local">'Imatinib'</a> below.)</p><p class="headingAnchor" id="H913434479"><span class="h3">Cataracts</span><span class="headingEndMark"> — </span>A cataract is an opacity of the lens of the eye that is most often age related. Uncommonly, cataracts may be a long-term side effect of antiestrogenic drugs, such as <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="10164" href="/d/drug information/10164.html" rel="external">toremifene</a>, as well as the alkylating agent <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>. (See  <a class="medical medical_review" href="/d/html/6904.html" rel="external">"Cataract in adults"</a> and <a class="local">'Tamoxifen and toremifene'</a> below.)</p><p>Cataracts are painless, and they present with slow progressive vision loss. Patients can complain of glare or halos around lights at nighttime. If visually significant and affecting activities of daily living, cataract extraction with intraocular lens placement can be considered. (See  <a class="medical medical_review" href="/d/html/6904.html" rel="external">"Cataract in adults", section on 'Surgical treatment'</a>.)</p><p class="headingAnchor" id="H27977948"><span class="h2">Uveitis and ocular inflammation</span><span class="headingEndMark"> — </span>Uveitis refers to inflammation of the uvea; the anterior portion of the uvea includes the iris and ciliary body, and the posterior portion of the uvea is known as the choroid  (<a class="graphic graphic_figure graphicRef57690" href="/d/graphic/57690.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Definitions'</a>.)</p><p>Ocular inflammation associated with chemotherapy (<a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, immune checkpoint inhibitors, BRAF inhibitors, the small-molecule EGFR inhibitor <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, the bispecific anti-EGFR and MET receptor inhibitor <a class="drug drug_general" data-topicid="131693" href="/d/drug information/131693.html" rel="external">amivantamab</a>, the Bruton tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">ibrutinib</a>) can present as anterior uveitis, intermediate uveitis, posterior uveitis (retinitis or choroiditis), or panuveitis (entire eye), including Vogt-Koyanagi-Harada syndrome (VKH). (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Symptoms and findings'</a> and  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Systemic inflammatory diseases'</a> and <a class="local">'BRAF inhibitors'</a> below and <a class="local">'Epidermal growth factor receptor (EGFR) inhibitor'</a> below and <a class="local">'Immune checkpoint inhibitors'</a> below and <a class="local">'Cytarabine and fludarabine'</a> below and <a class="local">'Bruton tyrosine kinase inhibitors'</a> below.)</p><p>The symptoms of uveitis, which are all nonspecific, depend upon the portion of the uveal tract that is involved; visual loss may occur with anterior, intermediate, or posterior involvement (see  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Differential diagnosis'</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anterior uveitis</strong> – Inflammation of the anterior uveal tract, characterized by the presence of leukocytes in the anterior chamber of the eye, is called anterior uveitis and is synonymous with iritis. When the adjacent ciliary body is also inflamed, the process is known as iridocyclitis [<a href="#rid12">12</a>]. Anterior uveitis may produce pain and redness, although these symptoms are minimal if inflammation begins insidiously. In anterior uveitis (iritis), the redness, if present, is primarily noted at the limbus (the junction between the cornea and the sclera  (<a class="graphic graphic_figure graphicRef73347" href="/d/graphic/73347.html" rel="external">figure 3</a>)); such patients often have photophobia and pain. The degree of visual loss associated with anterior uveitis is variable.</p><p></p><p class="bulletIndent1">The presence of leukocytes in the anterior chamber of the eye on slit lamp examination is characteristic of anterior uveitis but is nonspecific. (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p></p><p class="bulletIndent1">Leukocytes are not normally found in the aqueous humor that fills the space between the cornea and the lens. A haze, described by ophthalmologists as a "flare," may also be appreciated by slit lamp examination and reflects protein accumulation in the aqueous humor secondary to disruption of the blood-aqueous barrier.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Posterior and intermediate uveitis</strong> – The presence of leukocytes in the vitreous humor and evidence of active chorioretinal inflammation are diagnostic of intermediate uveitis and posterior uveitis, respectively. In contrast to anterior uveitis, posterior or intermediate uveitis is more likely to be painless but may result in nonspecific visual changes, such as floaters and/or reduced visual acuity. Redness of the eye is not a prominent feature of posterior inflammation unless there is an accompanying anterior uveitis.</p><p></p><p class="bulletIndent1">In posterior or intermediate uveitis, direct visualization of active chorioretinal inflammation and/or leukocytes in the vitreous humor can be detected on ophthalmic examination. Complete examination of the eye posterior to the lens usually includes a technique called scleral depression. This maneuver allows the examiner to look for an inflammatory exudate over the pars plana, the portion of the eye just between the retina and the ciliary body.</p><p></p><p class="bulletIndent1">Terms used to describe forms of uveitis posterior to the lens include vitritis, intermediate uveitis, pars planitis, choroiditis, retinitis, chorioretinitis, and retinochoroiditis [<a href="#rid12">12</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panuveitis</strong> – Panuveitis is defined as simultaneous inflammation in the anterior chamber, vitreous humor, and retina or choroid. It causes severe eye pain, photophobia, conjunctival injection, vision loss, and the presence of floaters. In patients with panuveitis, inflammation is detected simultaneously in all three areas, either by use of a slit lamp in conjunction with special lenses to focus the beam posterior to the lens or by use of an indirect ophthalmoscope and a handheld lens.</p><p></p><p>An important step in the initial evaluation of suspected uveitis is to rule out infection (eg, endophthalmitis) or other disorders that can mimic uveitis  (<a class="graphic graphic_table graphicRef75844" href="/d/graphic/75844.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Differential diagnosis'</a>.)</p><p>Patients with suspected uveitis should be referred promptly to an ophthalmologist for diagnosis and treatment. Prompt treatment is recommended to control inflammation and prevent further vision loss. Treatment includes frequent topical corticosteroid drops to reduce inflammation and topical cycloplegic agents to prevent iris synechiae and decrease ciliary body spasms to help with pain. Periocular or intraocular steroid injections and systemic (oral) corticosteroids are sometimes needed, especially for posterior and panuveitis. Corticosteroid use can lead to elevated intraocular pressures, cataracts, and potential blindness, so close follow-up is recommended. (See  <a class="medical medical_review" href="/d/html/5592.html" rel="external">"Uveitis: Treatment"</a>.)</p><p class="headingAnchor" id="H1089270381"><span class="h3">Episcleritis</span><span class="headingEndMark"> — </span>Episcleritis is an inflammation of the connective tissue between the conjunctiva and the sclera  (<a class="graphic graphic_figure graphicRef62615" href="/d/graphic/62615.html" rel="external">figure 4</a>). It is reported with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>. (See <a class="local">'Immune checkpoint inhibitors'</a> below.)</p><p>Patients usually complain of the abrupt onset of redness, irritation, and watering of the eye; pain is typically minimal, and vision is preserved. Physical examination reveals bright-red episcleral discoloration caused by vasodilatation of the superficial episcleral vessels and edema of the episclera  (<a class="graphic graphic_picture graphicRef76962" href="/d/graphic/76962.html" rel="external">picture 11</a>) without edema or thinning of the sclera. (See <a class="local">'Immune checkpoint inhibitors'</a> below and  <a class="medical medical_review" href="/d/html/5610.html" rel="external">"Episcleritis"</a>.)</p><p>Other disorders that may cause a red eye and other features that can resemble elements of episcleritis include scleritis, conjunctivitis, subconjunctival hemorrhage, blepharitis, keratitis, acute anterior uveitis, and acute angle-closure glaucoma. These conditions can generally be distinguished from episcleritis based upon the history and examination of the eye. (See  <a class="medical medical_review" href="/d/html/6900.html" rel="external">"The red eye: Evaluation and management"</a>.)</p><p>Symptomatic relief is the goal of therapy and can be accomplished with topical lubricants (<a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>), oral nonsteroidal anti-inflammatory drugs (NSAIDs), or topical glucocorticoids.</p><p class="headingAnchor" id="H27977954"><span class="h2">Orbit and periorbital tissue</span><span class="headingEndMark"> — </span>The eyelids, nasolacrimal drainage system, and periorbital soft tissues can all be affected by chemotherapy.</p><p class="headingAnchor" id="H27977960"><span class="h3">Trichiasis and trichomegaly</span><span class="headingEndMark"> — </span>Trichiasis (misdirection of eyelashes  (<a class="graphic graphic_picture graphicRef129038" href="/d/graphic/129038.html" rel="external">picture 12</a>)) and trichomegaly (abnormal eyelash length and texture), both complications of epidermal growth factor pathway inhibitors, can lead to corneal abrasions and a foreign body sensation. (See <a class="local">'Epidermal growth factor receptor (EGFR) inhibitor'</a> below and <a class="local">'Fibroblast growth factor receptor (FGFR) inhibitors'</a> below.)</p><p>Lubrication with <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> can help with comfort. Mechanical epilation of the abnormal eyelashes can temporarily solve the problem, providing sometimes dramatic relief. Electrolysis, radiofrequency epilation, cryotherapy, and surgical resection are alternative options, although they are less likely to be necessary, as reported side effects tend to resolve after cessation of therapy.</p><p class="headingAnchor" id="H27977966"><span class="h3">Cicatricial eyelid changes</span><span class="headingEndMark"> — </span>Cicatricial (scarring) changes to the eyelid, such as ectropion  (<a class="graphic graphic_picture graphicRef72737" href="/d/graphic/72737.html" rel="external">picture 4</a>), can prevent good eyelid closure and potentially result in exposure keratopathy, leading to symptoms of dry eye. This condition is reported with epidermal growth factor pathway inhibitors, <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a>, and <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>. (See <a class="local">'Epidermal growth factor receptor (EGFR) inhibitor'</a> below and <a class="local">'Fluoropyrimidines'</a> below and <a class="local">'Pemetrexed and eye edema'</a> below.)</p><p>Referral to an ophthalmologist is recommended for management. In the interim, patients may be prescribed an ocular lubricant.</p><p class="headingAnchor" id="H1748609305"><span class="h3">Chalazia and other eyelid masses</span><span class="headingEndMark"> — </span>Chalazia  (<a class="graphic graphic_picture graphicRef80892" href="/d/graphic/80892.html" rel="external">picture 5</a> and <a class="graphic graphic_picture graphicRef62030" href="/d/graphic/62030.html" rel="external">picture 6</a>) have been reported with the proteasome inhibitor <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>. Large, painful, inflamed, erythematous and nodular lesions appear over days on the upper or lower lids. Conservative management with warm compresses and lid hygiene, antibiotic and steroid ophthalmic ointments, and systemic <a class="drug drug_general" data-topicid="9986" href="/d/drug information/9986.html" rel="external">tetracycline</a> has been mildly successful, and management is difficult. Incision and drainage can help treat the lesion, but chalazia can recur as long as the drug is continued. (See <a class="local">'Bortezomib and eyelid disorders'</a> below.)</p><p>Other eyelid lesions, such as verruca vulgaris<em>, </em>keratoacanthomas, and squamous cell carcinomas, have been reported with the use of <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> and the BRAF inhibitors <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> and <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>. Squamoproliferative lesions that develop during chemotherapy with these agents should be treated similarly to lesions that develop in patients not receiving the drug (usually with complete surgical excision). Patients are usually able to continue the drug, but close clinical follow-up during treatment is warranted. (See  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'Squamoproliferative lesions'</a> and <a class="local">'BRAF inhibitors'</a> below and <a class="local">'Tyrosine kinase inhibitors'</a> below.)</p><p class="headingAnchor" id="H496078720"><span class="h3">Periorbital edema</span><span class="headingEndMark"> — </span>Periorbital edema is a common complaint in patients treated with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. Large lower-eyelid festoons (redundant folds of lax skin and orbicularis oculi muscle that hang below the lower eyelid) are rarely reported with this agent. These lesions can prevent proper eyelid closure, and they can be very difficult to manage. Referral to an oculoplastics specialist is recommended. (See <a class="local">'Imatinib'</a> below.)</p><p>Another drug associated with eye edema is <a class="drug drug_general" data-topicid="122066" href="/d/drug information/122066.html" rel="external">pexidartinib</a>, an oral kinase inhibitor approved for patients with advanced tenosynovial giant cell tumor not amenable to surgery. (See <a class="local">'Pexidartinib'</a> below.)</p><p class="headingAnchor" id="H1906097479"><span class="h3">Epiphora and nasolacrimal duct obstruction</span><span class="headingEndMark"> — </span>Epiphora (excess tearing), with or without nasolacrimal duct or canalicular obstruction, has been associated with fluoropyrimidines and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a>, especially when administered weekly. <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> has also been associated with epiphora. Referral to an ophthalmologist for probing and irrigation of the nasolacrimal system is the most reliable method to rule out duct obstruction in these cases. Prophylactic silicone intubation is appropriate for patients with progressive ductal stenosis to prevent permanent complete closure and the need for much more involved surgery, and worse outcomes [<a href="#rid13">13</a>]. (See <a class="local">'Epiphora and docetaxel'</a> below and <a class="local">'Fluoropyrimidines'</a> below and <a class="local">'Imatinib'</a> below.)</p><p class="headingAnchor" id="H1598595631"><span class="h3">Orbital inflammation</span><span class="headingEndMark"> — </span>Inflammation of the orbit (sometimes referred to as being similar to Graves ophthalmopathy, although rarely true Graves ophthalmopathy) has been reported with the immune checkpoint inhibitor <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid14">14</a>]. It can cause eye pain with eye movement, orbital congestion (conjunctival injection and chemosis), proptosis of the eye, exposure keratopathy, ophthalmoplegia and diplopia, strabismus, potential optic neuropathy, and blindness. This is an emergency, and prompt evaluation with a specialist is recommended. Before getting to the specialist, maneuvers that can be undertaken are checking for complete eyelid closure to protect the cornea and prevent exposure keratopathy, and starting a topical ophthalmic lubricant gel right away. Evaluate for optic neuropathy by looking for decreased visual acuity, an afferent pupillary defect, color desaturation testing, and constriction on visual fields on confrontation. Extraocular muscle movements and symptoms of diplopia should be checked as well.</p><p class="headingAnchor" id="H27977984"><span class="h2">Retina</span><span class="headingEndMark"> — </span>Several chemotherapy drugs have been reported to affect retinal vasculature, causing retinal vein and artery occlusions, intraretinal hemorrhages and cotton wool spots, choroidal neovascularization (a form of macular degeneration), toxicity to the retinal pigment epithelium leading to pigmentary retinopathy, accumulation of fluid under the retinal pigment epithelium (central serous retinopathy), as well as intraretinal (cystoid macular edema) and subretinal damage (serous retinal detachments). Chemotherapy agents can also accumulate in the retinal pigment epithelium, causing refractile retinal deposits. Photoreceptors can also be affected, leading to impaired night vision [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H1785385097"><span class="h3">Retinal vein and artery occlusion</span><span class="headingEndMark"> — </span>Occlusions of the retinal artery or vein, which have been reported with interferon and mitogen-activated protein kinase (MEK) inhibitors, cause blurred vision and painless acute vision loss, which can be profound. (See <a class="local">'Interferon'</a> below and <a class="local">'Mitogen-activated protein kinase inhibitors'</a> below and <a class="local">'Carmustine and retinal damage'</a> below.)</p><p>Retinal ischemia from artery occlusion &gt;90 minutes generally causes irreversible vision loss. No treatment has been definitively shown to be effective to prevent the vision loss once it occurs. Recommendations include immediate cessation of therapy and referral to a retina specialist. (See  <a class="medical medical_review" href="/d/html/5236.html" rel="external">"Central and branch retinal artery occlusion"</a>.)</p><p>For retinal vein occlusions, referral to a retina specialist is indicated for consideration of intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors to optimize vision. (See  <a class="medical medical_review" href="/d/html/15263.html" rel="external">"Retinal vein occlusion: Treatment", section on 'Vascular endothelial growth factor inhibitors'</a>.)</p><p class="headingAnchor" id="H3668957106"><span class="h3">Choroidal neovascularization</span><span class="headingEndMark"> — </span>There is a single case report of multifocal choroidal neovascularization in a patient treated with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H1960827992"><span class="h3">Macular edema, central serous retinopathy, and serous retinal detachment</span><span class="headingEndMark"> — </span>Cystoid macular edema is defined as multiple cyst-like (cystoid) areas of fluid appearing in the central retina (macula) and causing retinal swelling or edema. It presents with painless blurry vision or metamorphopsia (distortion of lines; for example, straight lines appear wavy).</p><p>Multiple chemotherapy agents have been associated with macular edema, including <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>, <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, interferon, <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, taxanes, and <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>. (See <a class="local">'BRAF inhibitors'</a> below and <a class="local">'Tyrosine kinase inhibitors'</a> below and <a class="local">'Tamoxifen and toremifene'</a> below and <a class="local">'Platinum analogs'</a> below and <a class="local">'Taxanes'</a> below and <a class="local">'Interferon'</a> below.)</p><p>When cystoid macular edema results from uveitis (as, for example, with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>), photophobia can also present if there is active associated inflammation. (See <a class="local">'Uveitis and ocular inflammation'</a> above and <a class="local">'BRAF inhibitors'</a> below.)</p><p>MEK inhibitors are all associated with retinopathy as a class effect, although the terms used to describe this toxicity are varied. Symptomatic patients may complain of blurred vision, altered color perception, shadows, light sensitivity, metamorphopsia and/or glare. Symptoms generally resolve either spontaneously or after discontinuation of therapy. (See <a class="local">'Mitogen-activated protein kinase inhibitors'</a> below.)</p><p>Serous retinal detachments (as have been seen with <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, and inhibitors of fibroblast growth factor receptor [FGFR]) are associated with painless vision loss. (See <a class="local">'Human epidermal growth factor receptor 2 (HER2) inhibitors'</a> below and <a class="local">'Fibroblast growth factor receptor (FGFR) inhibitors'</a> below.)</p><p>In severe cases, patients complain of a dark curtain-like effect coming from any direction, with or without photopsia (flashes of light). Prompt evaluation by an ophthalmologist is recommended for all patients with visual changes while receiving chemotherapy. Resolution of serous retinal detachments can occur with cessation of treatment.</p><p class="headingAnchor" id="H2402245080"><span class="h3">Pigment changes, cotton wool spots, and hemorrhages</span><span class="headingEndMark"> — </span>Retinal pigmentary changes, cotton wool spots, and mild intraretinal hemorrhages are signs of damage to various layers of the retina. Usually, the cotton wool spots and intraretinal hemorrhages are signs of inner retinal damage, while the pigmentary changes are associated with outer retinal damage. Cotton wool spots reflect ischemic damage, while intraretinal hemorrhages and pigmentary changes can be due to either ischemia or other causes, such as inflammation. Reports range from asymptomatic to mild painless blurriness of vision. Visual prognosis depends on the agent. (See <a class="local">'Carmustine and retinal damage'</a> below and <a class="local">'Interferon'</a> below.)</p><p>Reports of retinal deposits from <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> range from asymptomatic to mild painless blurriness of vision. The nature of these deposits is unclear. They may represent potential changes to the retinal structure (ie, postinflammatory or degenerative changes) or drug deposits. Pigmentary changes are generally irreversible, but visual disturbance can resolve with cessation of therapy. Follow-up with an ophthalmologist for monitoring is recommended. (See <a class="local">'Tamoxifen and toremifene'</a> below.)</p><p class="headingAnchor" id="H27978008"><span class="h2">Optic nerve</span><span class="headingEndMark"> — </span>Reports of optic neuropathy from chemotherapies include optic nerve edema, optic neuritis, optic atrophy, and idiopathic intracranial hypertension with associated cranial nerve palsies and optic nerve edema. In some cases, different authors have used different words to describe the same toxicity.</p><p class="headingAnchor" id="H480158"><span class="h3">Optic nerve edema</span><span class="headingEndMark"> — </span>Optic nerve edema has varying presentations: asymptomatic to mild-moderate blurriness of vision, enlarged blind spot, and constriction of visual field. Several agents have been associated with optic nerve edema, including <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, taxanes, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, and <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>. Drug-induced intracranial hypertension, such as that associated with <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> and <a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">all-trans retinoic acid</a> (systemic tretinoin), can also cause optic nerve edema and is associated with blurry vision, headaches, visual field constrictions, and nausea/vomiting. (See <a class="local">'Platinum analogs'</a> below and <a class="local">'All-trans retinoic acid'</a> below.)</p><p>Regardless of its etiology, edema of the optic nerve head can be seen on examination of the fundus. Magnetic resonance imaging (MRI) of the head and lumbar puncture with opening pressure can help to exclude structural defects raising intracranial pressure and to assess for the presence of intracranial hypertension.</p><p>Management of the drug is discussed below. (See <a class="local">'Imatinib'</a> below and <a class="local">'Platinum analogs'</a> below and <a class="local">'All-trans retinoic acid'</a> below and <a class="local">'Mitotane and retinopathy'</a> below and <a class="local">'Visual changes'</a> below and <a class="local">'Low-dose methotrexate and optic neuropathy'</a> below.)</p><p class="headingAnchor" id="H797190267"><span class="h3">Optic neuritis</span><span class="headingEndMark"> — </span>Optic neuritis, as has been reported with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, is associated with moderate to severe vision loss, color vision loss, and pain with eye movement. Optic neuritis that is due to ischemia, however, may be nonpainful. Examination of the optic nerve head can sometimes show either optic disc swelling, if it involves the anterior portion of the optic nerve, or no swelling, if it involves the posterior portions. An MRI with contrast and dedicated orbital cuts can help with diagnosis. Patients may have an afferent pupillary defect if one optic nerve is involved more than the other. (See <a class="local">'Imatinib'</a> below.)</p><p class="headingAnchor" id="H1072003953"><span class="h3">Atrophy</span><span class="headingEndMark"> — </span>Optic nerve atrophy that follows an ischemic injury can result from chronic optic nerve edema or optic neuritis, or represent an idiopathic drug toxicity (interferon, <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, low-dose oral <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>). It presents with a slow progressive vision loss. An afferent pupillary defect can be seen if the relative damage of one nerve is more severe than that of the other. The optic nerve head may appear pale on examination. (See <a class="local">'Interferon'</a> below and <a class="local">'Platinum analogs'</a> below and <a class="local">'Vincristine'</a> below and <a class="local">'Low-dose methotrexate and optic neuropathy'</a> below.)</p><p>Etiologies and clinical features of nonarteritic anterior ischemic optic neuropathy are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/5233.html" rel="external">"Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies"</a> and  <a class="medical medical_review" href="/d/html/5256.html" rel="external">"Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis"</a>.)</p><p class="headingAnchor" id="H3887581951"><span class="h1">TOXICITY PROFILE OF SPECIFIC AGENTS</span></p><p class="headingAnchor" id="H27978032"><span class="h2">Molecularly targeted agents</span></p><p class="headingAnchor" id="H27978048"><span class="h3">Epidermal growth factor receptor (EGFR) inhibitor</span><span class="headingEndMark"> — </span>Agents targeting the EGFR (including the monoclonal antibodies <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>, and <a class="drug drug_general" data-topicid="131693" href="/d/drug information/131693.html" rel="external">amivantamab</a>, and the small-molecule EGFR inhibitors <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>, and <a class="drug drug_general" data-topicid="132715" href="/d/drug information/132715.html" rel="external">mobocertinib</a>) have some of the highest frequencies of ocular side effects.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cornea and anterior segment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Multiple different ocular toxicities are reported with <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, most of which affect the anterior segment. These include corneal erosions [<a href="#rid9">9</a>], eyelash trichomegaly [<a href="#rid17">17-21</a>], keratitis (inflammation of the cornea) [<a href="#rid22">22</a>], conjunctivitis, eyelid dermatitis, and blepharitis [<a href="#rid19">19,23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Panitumumab-related ocular toxicities include conjunctivitis, conjunctival hyperemia, corneal perforation and keratitis (including ulcerative keratitis) [<a href="#rid24">24</a>], epiphora, and eyelid irritation.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Reported ocular toxicities in patients treated with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> include conjunctivitis and eyelid changes such as entropion, ectropion, and trichomegaly, although early episcleritis and corneal epithelial defects with associated infectious keratitis are reported.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical trials with <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a> have reported mostly dry eye, blepharitis, conjunctivitis, and visual disturbances such as hemianopia, blurred vision, and photophobia, but corneal erosions, trichomegaly, and punctate keratopathy have also been reported [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A clinical trial of <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F215310s000lbl.pdf&amp;token=QBvZD2H7TQ6hHpKbbt%2FLna1v4ZY1boshL2z8%2FmKoU87KSzqh9jTUvI0pXZ8imBYc7O6GcKUsPRWE6KewAannCG1fIe4%2FGWSF7%2B0ssaMRQ%2BQ%3D&amp;TOPIC_ID=96203" target="_blank">mobocertinib</a> reported ocular toxicity in (including dry eye, eye pruritus, eye discharge, blepharitis, trichiasis, conjunctival hemorrhage, blurred vision, and corneal edema) in 11 percent; none were grade 3 or worse.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Poor healing of the outermost epithelial layer of the cornea is reported with all EGFR inhibitors, leading to dry eyes [<a href="#rid26">26</a>] and persistent corneal epithelial defects and erosions [<a href="#rid9">9,10,27,28</a>]. This can cause significant blurriness of vision [<a href="#rid9">9</a>] and can increase risks of bacterial keratitis [<a href="#rid27">27</a>]. Standard treatment with frequent <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>, bandage contact lens, and patching can be tried [<a href="#rid9">9</a>], but good results are infrequent. Epithelial defects are reversible with cessation of treatment [<a href="#rid27">27</a>]. The decision to continue therapy must individualized, taking into account the risks and the availability of alternative treatments. Consistent follow-up with an ophthalmologist is recommended if the patient is to continue the EGFR inhibitor, in order to manage symptoms and monitor for signs of superinfection. (See <a class="local">'Corneal epithelial defects'</a> above.)</p><p></p><p class="bulletIndent1">Corneal thinning and melts that are sterile (culture negative) are more rare with this class of agents (and are reported most often with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>), but they are potentially more severe, as corneal perforation can result [<a href="#rid10">10,24,29</a>]. Cyanoacrylate glue can temporize the thinning [<a href="#rid29">29</a>]. Cessation of the offending medication can halt progression of thinning, but ultimately, corneal transplantation may be necessary. Given the potential for severe vision loss, we recommend establishing regular follow-ups with an ophthalmologist in any patient who develops ocular symptoms (blurred vision, dry eyes, burning or stinging of the eyes) while receiving an anti-EGFR agent.</p><p></p><p class="bulletIndent1">Keratitis is also reported with <a class="drug drug_general" data-topicid="131693" href="/d/drug information/131693.html" rel="external">amivantamab</a>, which is a bispecific antibody that targets both the EGFR and the MET receptor. In a safety population of 129 patients treated with the drug, 0.7 percent developed keratitis [<a href="#rid30">30</a>]. Other symptoms included dry eye, conjunctival redness, blurred vision, ocular itching, visual impairment, and uveitis (0.3 percent). The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F761210s000lbl.pdf&amp;token=V7M4gZishJOi05Y39BpDdUQMM28QcCOPas05JOZktjmrHVzrnn7vdXVn0S6GkDcPK41OyD5%2BBW4n%2B1%2FZhTLri1o5V5blzBhs4vu3MXINvxY%3D&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for amivantamab</a> recommends prompt referral of patients with eye symptoms to an ophthalmologist, and dose modification guidelines are provided based upon symptom severity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anterior</strong> <strong>uveitis</strong> – Rare cases of severe anterior uveitis are reported in association with <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a> [<a href="#rid31">31,32</a>]. Drug discontinuation and management with topical corticosteroids is usually effective. Rechallenge with erlotinib caused recurrence of uveitis in one patient [<a href="#rid32">32</a>]. Referral to an ophthalmologist during an acute episode is recommended. If an alternative anticancer agent is not available, the risks must be weighed against the benefits of continued therapy in a discussion that involves the patient, the oncologist, and the ophthalmologist. (See <a class="local">'Uveitis and ocular inflammation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orbit and periorbital tissue</strong> – All EGFR inhibitors have been associated with dysregulated hair cycles leading to hypertrichosis or alopecia; changes in hair color, growth rate, and texture; and trichomegaly [<a href="#rid17">17-21</a>]. In a prospective study of 30 patients receiving <a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> or <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, the incidence of trichomegaly was 17 to 23 percent [<a href="#rid33">33</a>]. Trichiasis with eyelashes directed at the cornea has been reported [<a href="#rid9">9,34,35</a>], in some cases causing corneal ulcer [<a href="#rid35">35,36</a>], which is vision threatening and needs immediate treatment. This is particularly hazardous in patients who also have concurrent nonhealing corneal epithelium, as was reported in one case [<a href="#rid9">9</a>]. (See <a class="local">'Trichiasis and trichomegaly'</a> above.)</p><p></p><p class="bulletIndent1">Periocular skin changes are also relatively common, including edema, erythema, and blepharitis [<a href="#rid9">9,10,19,23,26,36,37</a>]. Periocular tissue may also be affected [<a href="#rid9">9,10,17-19,26,33,36-44</a>]. Chronic inflammation leads to hyperpigmentation and cicatricial changes, such as ectropion, which can lead to poor eyelid closure, exposure keratopathy, and tearing [<a href="#rid10">10,36,37,45</a>].</p><p></p><p class="bulletIndent1">These side effects are generally mild and reversible when treatment is discontinued. Symptomatic management is usually successful and permits ongoing treatment with the anti-EGFR agent. However, an ophthalmologic evaluation is recommended to ensure that the cornea is not compromised. (See <a class="local">'Blepharitis and meibomian gland dysfunction'</a> above and <a class="local">'Cicatricial eyelid changes'</a> above.)</p><p></p><p class="headingAnchor" id="H27978054"><span class="h3">Human epidermal growth factor receptor 2 (HER2) inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> is a monoclonal antibody directed against HER2; it is used for treatment of HER2-ovexpresssing breast and gastric cancers. <a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">Ado-trastuzumab emtansine</a> is an antibody-drug conjugate composed of trastuzumab, a thioether linker, and a microtubule inhibitor, DM1. (See  <a class="medical medical_review" href="/d/html/15749.html" rel="external">"Systemic treatment for HER2-positive metastatic breast cancer"</a> and  <a class="medical medical_review" href="/d/html/773.html" rel="external">"Adjuvant systemic therapy for HER2-positive breast cancer", section on 'Trastuzumab-based treatment'</a> and  <a class="medical medical_review" href="/d/html/2473.html" rel="external">"Initial systemic therapy for locally advanced unresectable and metastatic esophageal and gastric cancer", section on 'HER2-overexpressing adenocarcinomas'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cornea and anterior segment</strong> – Dry eyes and the associated symptoms of tearing, mild blurriness of vision, and conjunctival injection were reported in 35 of 112 patients (31 percent) in a phase II study of the conjugate agent <a class="drug drug_general" data-topicid="88427" href="/d/drug information/88427.html" rel="external">ado-trastuzumab emtansine</a> [<a href="#rid46">46</a>]. <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> has also been associated with conjunctivitis.</p><p></p><p class="bulletIndent1">Symptom management with frequent <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> is usually successful and permits ongoing treatment. This is not a vision-threatening condition, and cessation of therapy is usually not necessary. (See <a class="local">'Dry eyes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retina</strong> – <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">Trastuzumab</a> has rarely been associated with macular edema, macular ischemia, and serous retinal detachment, which can lead to severe vision loss [<a href="#rid47">47</a>]. Medication should be stopped immediately, and referral to a retina specialist is recommended. (See <a class="local">'Macular edema, central serous retinopathy, and serous retinal detachment'</a> above.)</p><p></p><p class="headingAnchor" id="H27978060"><span class="h3">BRAF inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">Vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, and <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a> are orally available, potent inhibitors of the kinase domain in mutant <em>BRAF</em> (a serine-threonine kinase); all are approved for treatment of metastatic melanoma with a <em>BRAF</em><em><sup>V600</sup></em> mutation. (See  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p>Several ocular toxicities are reported with all three agents:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dry eyes/conjunctivitis</strong> – A review of 568 patients enrolled in <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> phase I clinical trials showed that dry eyes occurred in 2 percent and conjunctivitis occurred in 2.8 percent [<a href="#rid48">48</a>]. Symptoms are generally mild, and cessation of therapy is usually not necessary. (See <a class="local">'Dry eyes'</a> above and <a class="local">'Conjunctivitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Uveitis</strong> – <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">Vemurafenib</a> has been associated with uveitis (incidence of 4 percent in a review of phase I clinical trials [<a href="#rid48">48</a>]). Uveitis was diagnosed at a median of 117 days after starting treatment and was mild/moderate in this series. All cases were successfully managed by topical, periocular, or intraocular corticosteroid treatment. Some had dose reduction, but all were able to continue therapy. (See <a class="local">'Uveitis and ocular inflammation'</a> above.)</p><p></p><p class="bulletIndent1">Another study showed a higher incidence (7 out of 78 patients developed uveitis) and wider range of severity, ranging from mild anterior uveitis to severe panuveitis complicated by retinal detachment or macular edema [<a href="#rid49">49</a>]. The majority had clinical improvement with cessation of <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> and were able to be managed with local corticosteroids. A few recurred upon rechallenge. (See <a class="local">'Macular edema, central serous retinopathy, and serous retinal detachment'</a> above and <a class="local">'Uveitis and ocular inflammation'</a> above.)</p><p></p><p class="bulletIndent1">There are at least three case reports of posterior uveitis and bilateral panuveitis in patients treated with <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a> in conjunction with the mitogen-activated protein kinase (MEK) inhibitor <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a> [<a href="#rid50">50-52</a>]. In one report, uveitis resolved upon cessation of both drugs, with no sequelae [<a href="#rid50">50</a>]. Uveitis has responded to pulsed or topical steroid therapy [<a href="#rid51">51,52</a>].</p><p></p><p class="bulletIndent1">Uveitis, including iritis and iridocyclitis, has been reported in approximately 4 percent of patients receiving <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a> in combination with <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a> [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1">All patients receiving a BRAF inhibitor should be assessed for visual symptoms at each visit. The majority of cases can be managed successfully; prompt evaluation and management by an ophthalmologist are recommended if uveitis is suggested by clinical symptoms in patients receiving<em> </em>BRAF inhibitors. In mild cases, drug treatment can be continued. If there is no improvement on local therapy, treatment discontinuation is an option, as is using pulsed corticosteroids. Severe cases of panuveitis warrant discontinuation of therapy.</p><p></p><p class="bulletIndent1">In contrast to the other BRAF inhibitors, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F210496lbl.pdf&amp;token=wBi%2FdCaSEohuRLyaK1k6p%2FFnw%2F%2BhPuO5wQ4w41hBsQUR6BhwSyVNKA2H%2B6yknc7CpUfie%2BT9V%2FrJqzPc8fwdRDlNCKq2oIaE2QTW6wCS8l4%3D&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for encorafenib</a> contains a specific recommendation to perform an ophthalmologic evaluation at regular intervals and for any new or worsening disturbances. <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">Encorafenib</a> should be withheld for up to six weeks for grade 1 or 2 uveitis that does not respond to specific ocular therapy, or for any grade 3 uveitis  (<a class="graphic graphic_table graphicRef118296" href="/d/graphic/118296.html" rel="external">table 2</a>). If improved, resume at the same or a reduced dose; if not improved, discontinue permanently.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamoproliferative lesions</strong> – Clinically significant cutaneous side effects are common with <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, including squamous cell carcinomas and keratoacanthomas. Eyelid squamous cell carcinoma and verruca vulgaris lesions frequently occur as well [<a href="#rid54">54</a>]. Squamoproliferative lesions are also reported with the related agent <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, but eyelid neoplasms are not specifically reported.</p><p></p><p class="bulletIndent1">Most lesions develop during the first three months of therapy and may occur in sun-protected sites. Biopsy and excision by a specialist who can excise the lesions, reconstruct defects, and prevent poor eyelid closure to protect the eye are recommended. Patients are usually able to continue treatment without dose adjustment. (See  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'Squamoproliferative lesions'</a> and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p></p><p class="headingAnchor" id="H2041320767"><span class="h3">Mitogen-activated protein kinase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">Trametinib</a> and <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, which are inhibitors of the MEK enzymes MEK1 and MEK2, have significant clinical activity in melanoma patients whose tumor contains a <em>BRAF</em><em><sup>V600</sup></em> mutation; these MEK inhibitors are now largely used for treatment of advanced melanoma in combination with<em> </em>BRAF inhibitors, which also are associated with ocular toxicity. (See <a class="local">'BRAF inhibitors'</a> above and  <a class="medical medical_review" href="/d/html/15408.html" rel="external">"Systemic treatment of metastatic melanoma with BRAF and other molecular alterations", section on 'Toxicities of BRAF and MEK inhibitors'</a>.)</p><p>These and other MEK inhibitors (eg, <a class="drug drug_general" data-topicid="127843" href="/d/drug information/127843.html" rel="external">selumetinib</a>, <a class="drug drug_general" data-topicid="118324" href="/d/drug information/118324.html" rel="external">binimetinib</a>) have been associated with retinal damage, which takes two forms:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retinal vein occlusion</strong> – Retinal vein occlusion (RVO) is an uncommon but potentially severe side effect reported in initial clinical trials of several MEK inhibitors, including <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a> and <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>. Across all clinical trials, the incidence with trametinib was 0.2 percent (4 of 1749 individuals) [<a href="#rid55">55-58</a>]. Predisposing factors include glaucoma, uncontrolled hypertension, and diabetes mellitus. In at least one case, dosing adjustment from a continuous to an intermittent schedule reduced the frequency of RVO [<a href="#rid59">59</a>]. (See <a class="local">'Retinal vein and artery occlusion'</a> above.)</p><p></p><p class="bulletIndent1">At least one series suggests an association of MEK inhibitor-associated RVO with hyperhomocysteinemia, an inborn error of metabolism that predisposes to venous thromboembolism [<a href="#rid60">60</a>]. These scant data indicate a potential role for hyperhomocysteinemia screening prior to initiation of MEK inhibitor therapy, but more data are needed. (See  <a class="medical medical_review" href="/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Hyperhomocysteinemia'</a>.)</p><p></p><p class="bulletIndent1">For patients who develop an RVO, referral to a retina specialist is indicated; intravitreal injection of vascular endothelial growth factor inhibitors may be needed to optimize vision in the right setting. (See  <a class="medical medical_review" href="/d/html/15263.html" rel="external">"Retinal vein occlusion: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retinopathy</strong> – Retinal events other than RVO have been reported for all MEK inhibitors tested in a clinical setting, and they are considered to represent a class effect. Various terms have been used to describe these side effects, which are based upon a combination of clinical findings and nonspecific symptoms, including serous retinopathy, central serous retinopathy, subfoveal retinal detachment, macular edema, visual disturbance, retinopathy, chorioretinopathy, and blurred vision [<a href="#rid55">55,61-70</a>]. All of these clinical findings correspond to the same clinical entity, and the umbrella term "MEK inhibitor-associated retinopathy" has been introduced to clarify this confusing area.</p><p></p><p class="bulletIndent1">The incidence of MEK inhibitor-associated retinopathy ranges from 5 to 75 percent [<a href="#rid66">66,71,72</a>]. In a phase III trial of <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a> alone or with <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, retinopathy was reported more frequently with combined treatment (26 versus 3 percent), and over one-half of cases were asymptomatic and discovered during routine monitoring [<a href="#rid69">69,73</a>]. MEK inhibitor-associated retinopathy usually presents acutely within the first week of the first dose. The clinical examination of mild presentations is typically characterized by small, multifocal and bilateral subretinal detachments, which may be accompanied by subretinal fluid  (<a class="graphic graphic_diagnosticimage graphicRef113466" href="/d/graphic/113466.html" rel="external">image 1</a>) [<a href="#rid68">68</a>]. Moderate cases may be characterized by only multiple subretinal detachments. More severe cases may develop intraretinal fluid or cysts, and a disarrangement of the outer retinal layers. The clinical presentation is often but not always bilateral and is most often symmetric [<a href="#rid74">74</a>].</p><p></p><p class="bulletIndent1">Symptoms vary widely; in many cases, patients are asymptomatic [<a href="#rid66">66</a>]. Symptomatic patients may complain of blurred vision, altered color perception, shadows, light sensitivity, metamorphopsia, and/or glare. Symptoms generally (but not always [<a href="#rid73">73</a>]) resolve either spontaneously or after discontinuation of therapy [<a href="#rid61">61,62,69</a>].</p><p></p><p>The United States Prescribing Information for both <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D0002ad27-779d-42ab-83b5-bc65453412a1&amp;token=T68o8mlcliPDZY2b7XwmuI3hgwW%2BBDlcns%2FQinTihLzYPVpelj5TbnxFYjhpc58OasY32O7M2vKkBQGe9tZnBXpy5CS5VmwNXOVp%2BSuVwNIA5g9RT711PrJiE57tVej5&amp;TOPIC_ID=96203" target="_blank">trametinib</a> and <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dc387579e-cee0-4334-bd1e-73f93ac1bde6&amp;token=ZmpD6p9oKlUR4zH1zocX47UoxpCj5bbQOe6iMEIIS8fQ6w0%2BwR35RsVXZmUo2Xqo1f%2BtIs%2BE1jxCtOrkZ5irh8PZ6Bt8gubDEBBkB9A1tLKtZyBkBCJwLYPm7nR0M8NA&amp;TOPIC_ID=96203" target="_blank">cobimetinib</a> recommends ophthalmological examination at regular intervals during therapy and at any time a new or worsening visual disturbance is reported. <a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">Trametinib</a> should be withheld for documented retinal detachment, and restarted at a lower dose if resolution is documented within three weeks. If no improvement after three weeks, recurrence, or RVO, discontinue use of the drug [<a href="#rid57">57</a>]. For <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>, interrupt therapy for serous retinopathy until visual symptoms improve. Resume at a reduced dose only if symptoms improve over four weeks. For recurrent symptoms or any RVO, discontinue the drug permanently.</p><p class="headingAnchor" id="H3898222410"><span class="h3">Fibroblast growth factor receptor (FGFR) inhibitors</span><span class="headingEndMark"> — </span>Several inhibitors of FGFR (including <a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">ponatinib</a>, dovitinib, <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a>, <a class="drug drug_general" data-topicid="127947" href="/d/drug information/127947.html" rel="external">pemigatinib</a>, and <a class="drug drug_general" data-topicid="131754" href="/d/drug information/131754.html" rel="external">infigratinib</a>) are in clinical trials for a variety of malignancies. Erdafitinib has now been approved for the treatment of advanced urothelial cancers that harbor certain <em>FGFR</em> mutations, and both pemigatinib and infigratinib are approved for previously treated advanced cholangiocarcinomas that harbor <em>FGFR2</em> gene alterations. (See  <a class="medical medical_review" href="/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract", section on 'FGFR mutation negative'</a> and  <a class="medical medical_review" href="/d/html/2524.html" rel="external">"Systemic therapy for advanced cholangiocarcinoma", section on 'FGFR inhibitors for FGFR fusion-positive tumors'</a>.)</p><p>All of these drugs appear to be associated with a similar type of serous retinopathy (foci of subretinal fluid) to that seen with the MEK inhibitors [<a href="#rid71">71,75-79</a>], possibly because the FGFR pathway intersects with the MEK pathway.</p><p>As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In the phase II BLC2001 trial, which included 87 patients with locally advanced or metastatic urothelial cancer that had susceptible <em>FGFR2</em> or <em>FGFR3</em> mutations, ocular toxicity from <a class="drug drug_general" data-topicid="121054" href="/d/drug information/121054.html" rel="external">erdafitinib</a> resulting in a visual field defect was reported in 25 percent, with a median time to first onset of 50 days [<a href="#rid80">80</a>]. Grade 3 symptoms, defined as involving the central field of vision causing vision worse than 20/40 or &gt;3 lines of worsening from baseline, were reported in 3 percent of patients. Dry eye symptoms occurred in 28 percent of patients during treatment and were grade 3 in 6 percent. Ocular symptoms resolved in 13 percent and were ongoing at the study cutoff in 13 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the phase II FIGHT-202 trial, serous retinal detachment due to subretinal fluid accumulation occurred in six (4 percent) of 146 patients treated with <a class="drug drug_general" data-topicid="127947" href="/d/drug information/127947.html" rel="external">pemigatinib</a>; all events were grade 1 or 2, except for one grade 3 event that was deemed unrelated to therapy [<a href="#rid77">77</a>]. Only one patient required dose interruption because of this adverse event.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the PACE trial, ocular toxicities occurred in 30 percent of 449 patients; 3.6 percent experienced a serious or severe toxicity. The most frequent reported toxicities were dry eye, blurred vision, and eye pain [<a href="#rid81">81</a>]. Retinal toxicity occurred in 3.6 percent, and the most frequent were macular edema, retinal vein occlusion, retinal hemorrhage, and venous floaters.</p><p></p><p>Dry eyes and eyelash trichomegaly are also reported with this class of agents [<a href="#rid77">77-79,82</a>], as are corneal epithelial lesions [<a href="#rid28">28</a>].</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F212018s000lbl.pdf&amp;token=XTAZGyRz0YcnrQfx%2Fqf9v1ZIATObTL%2BCKKXdMjfkpOs8lcBRmLLwBOQfPAB2rYZ%2Fu%2B5hy%2BMKuP3QchQHc2txvYJU4Mfj0h6VX8Oiby%2BOc5M%3D&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for erdafitinib</a> recommends that all patients receive dry eye prophylaxis with ocular lubricants as needed. Monthly ophthalmologic examinations (including an assessment of visual acuity, slit lamp examination, fundus examination, and optical coherence tomography [OCT]) are recommended during the first four months of treatment and every three months thereafter, with urgent reevaluation at any time for visual symptoms. It is recommended that the drug be withheld when serous retinal toxicity occurs, regardless of vision, and permanently discontinued if it does not resolve in four weeks or if it is grade 4 in severity (ie, visual acuity 20/200 or worse in the affected eye). However, there were no data provided on the percentage of patients whose symptoms resolved within four weeks. There are also recommended dose modification guidelines for patients who develop ocular adverse reactions.</p><p>The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2020%2F213736s000lbl.pdf&amp;token=T7juFBR0rXPq74aD8nJPdd9iXc5aXRqA2kfMWc7rCifMs0dYKUuDbTbQbcsuJSVTE5t4YQVp0G5AJKpQqd1xD0gZeoTbb9HDM%2F5O%2B0j8jq4%3D&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for pemigatinib</a> recommends ophthalmologic examining including OCT prior to initiation of therapy, every two months for the first six months of treatment and every three months thereafter, and urgently at any time for visual symptoms. Specific dose modifications based on symptomatology and finding on serial examination are provided. A similar recommendation for ophthalmologic examining including OCT prior to therapy, at one and three months, and every three months thereafter is made in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F214622s000lbl.pdf&amp;token=AwJBMwgQiUFhnYK1m0c5X3J6cIs7m9m%2FUhF7%2BkM9M%2FuHisIc6VhkvAsfSZ8v72L9GAuAB2O7xBO7WqkZgraDdhA7ETY5z2gqRmGXOpiXZq4%3D&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for infigratinib</a>. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D16d804b6-4957-43ee-b18c-3b36ec37c5ac&amp;token=nsbS5wJ1GlqucnAGA7poM3kNGUyRdJarz6VRpayQi5EjOJV7XxYOx71RzaTCOfYpprifcxhl%2FflzxXHQND5vxXdFMKiPaug%2B2Tx6YjdIax9waRVDB6OX74D0w6TTQFvJ&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for ponatinib</a> suggests a comprehensive eye examination at baseline, and periodically during treatment.</p><p class="headingAnchor" id="H3617237055"><span class="h3">Immune checkpoint inhibitors</span><span class="headingEndMark"> — </span>Checkpoint inhibitors, which are immunomodulatory antibodies that are used to enhance the immune system function, have substantially improved the prognosis for patients with advanced melanoma and a number of other malignancies. (See  <a class="medical medical_review" href="/d/html/15863.html" rel="external">"Systemic treatment of metastatic melanoma lacking a BRAF mutation"</a>.)</p><p>The primary targets for checkpoint inhibition include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) – <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a>, an anti-CTLA-4 antibody, is approved for use in patients with advanced melanoma. It prolongs overall survival in advanced melanoma by increasing T-cell-mediated adaptive immunotherapy, but this is accompanied by numerous autoimmune toxicities, including colitis, hepatitis, thyroid function abnormalities, vitiligo, and hypophysitis. (See  <a class="medical medical_review" href="/d/html/96368.html" rel="external">"Toxicities associated with immune checkpoint inhibitors"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Programmed cell death-1 (PD-1) and programmed cell death-1 ligand (PD-L1) receptors – Multiple antibodies against PD-1 and PD-L1 have shown great promise in multiple malignancies. <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">Nivolumab</a> and <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, both of which target PD-1, and <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a>, <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>, and <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a>, which target PD-L1, have been approved in multiple indications (eg, melanoma, renal cell carcinoma, non-small cell lung cancer, head and neck cancer, urothelial carcinoma, Hodgkin lymphoma, Merkel cell carcinoma), and these agents are being evaluated in a wide range of other indications.</p><p></p><p class="headingAnchor" id="H44416784"><span class="h4">Ipilimumab</span><span class="headingEndMark"> — </span>There are a variety of ocular events reported in patients treated with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, including conjunctivitis, episcleritis, uveitis, and orbital inflammation (Graves-like ophthalmopathy).</p><p>Inflammation in the eyes presenting as anterior panuveitis [<a href="#rid83">83-86</a>] and episcleritis [<a href="#rid87">87</a>] are reported in patients taking <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, but the incidence is less than 1 percent. Symptoms can include photophobia, pain, dryness of the eyes, and blurred vision [<a href="#rid85">85</a>]. Vision loss is typically mild to moderate.</p><p><a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a> has rarely been associated with bilateral severe uveitis, which can lead to exudative retinal detachment in a mode similar to that seen with Vogt-Koyanagi-Harada syndrome (VKH). This can be vision threatening and should prompt immediate drug discontinuation [<a href="#rid87">87,88</a>]. (See <a class="local">'Uveitis and ocular inflammation'</a> above.)</p><p>Treatment with topical corticosteroid drops has controlled anterior uveitis, and vision usually improves. As patients typically have concurrent systemic autoimmune toxicities, systemic corticosteroids have also typically been used in these cases. While the uveitis appears to be manageable with corticosteroids, cessation of therapy must be considered in the setting of systemic autoimmune toxicity. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D2265ef30-253e-11df-8a39-0800200c9a66&amp;token=3QUMH5WHK71BHmrvuM8Sw7aqqAWKRQaoI%2B%2B7WeJQbJ1av2qJWXoPNTeyr7Zq77gaOOrFZxiYdzxefPly9KMjHtSBq7qZJsUSvpHxyNCvaPnqvafVBdAFepRl4MlSdwhK&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for ipilimumab</a> provides guidance for management of immune-mediated ocular toxicity:</p><p class="bulletIndent1"><span class="glyph">●</span>Administer corticosteroid eye drops (eg, 1 percent <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> acetate suspension) to patients who develop uveitis, iritis, or episcleritis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Permanently discontinue <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> for immune-mediated ocular disease grade 2 to 4 that is not improving to grade 1 within two weeks while receiving topical therapy, or that requires oral immunosuppressive therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If uveitis occurs in combination with other immune-mediated adverse reactions (eg, cutaneous [vitiligo, poliosis, alopecia], auditory [tinnitus], or neurologic [cerebrospinal fluid pleocytosis, meningismus] [<a href="#rid88">88,89</a>]), consider a VKH-like syndrome, which has been observed in patients treated with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> [<a href="#rid90">90</a>] and may require treatment with systemic steroids to reduce the risk of permanent vision loss.</p><p></p><p>Management guidelines for uveitis/iritis, episcleritis, and blepharitis caused by immune checkpoint inhibitor immunotherapy (including <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>), which in some cases differ from those in the United States Prescribing Information, are also available from the American Society of Clinical Oncology (ASCO). (See <a class="local">'ASCO guidelines for counseling and management'</a> below.)</p><p><a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a> has also been implicated in the development of orbital inflammation, which has been described as Graves-like orbitopathy, but only rarely is this truly thyroid-related [<a href="#rid91">91,92</a>]. Symptoms include proptosis, diplopia, exposure keratopathy, ophthalmoplegia (inability to move the ocular muscles), and enlargement of extraocular muscles, potentially compressing the optic nerve. A computed tomography (CT) scan of the orbits is helpful and will show enlargement of the extraocular muscles, classically with sparing of the tendon insertions. Lab studies with thyroid-stimulating hormone (TSH), thyroxine (T4), antithyroid peroxidase (TPO), and thyroglobulin antibodies are often positive (reflecting the association of ipilimumab with immune-mediated thyroiditis and hypothyroidism), but development of orbital inflammation can occur in euthyroid patients without positive serologies [<a href="#rid91">91</a>]. This condition is uncommon but severe and can be vision threatening. Prompt evaluation by a specialist is recommended to evaluate for orbital congestion, optic neuropathy, or exposure keratopathy. Acute treatment with systemic corticosteroids is recommended. Severe cases warrant cessation of therapy; however, it should be noted that the mean plasma half-life of ipilimumab is long (359 hours; 15 days) [<a href="#rid93">93</a>]. (See <a class="local">'Orbital inflammation'</a> above and  <a class="medical medical_review" href="/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a>.)</p><p class="headingAnchor" id="H495465160"><span class="h4">Anti-PD-1 and PD-L1 agents</span><span class="headingEndMark"> — </span>Intraocular inflammation (uveitis) following treatment with <a class="drug drug_general" data-topicid="96957" href="/d/drug information/96957.html" rel="external">pembrolizumab</a>, <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a>, or <a class="drug drug_general" data-topicid="119172" href="/d/drug information/119172.html" rel="external">cemiplimab</a> is a rare but clinically important event, described in approximately 1 percent of treated patients [<a href="#rid94">94-96</a>]. Ocular inflammation (uveitis, iritis) is also reported in fewer than 1 percent of patients receiving therapy with the anti-PD-L1 blocking antibodies <a class="drug drug_general" data-topicid="112481" href="/d/drug information/112481.html" rel="external">avelumab</a>, <a class="drug drug_general" data-topicid="112994" href="/d/drug information/112994.html" rel="external">durvalumab</a>, and <a class="drug drug_general" data-topicid="108314" href="/d/drug information/108314.html" rel="external">atezolizumab</a> [<a href="#rid97">97,98</a>].</p><p>Although the available data are limited, the risk of eye disorders may be aggravated when drugs of both checkpoint inhibitor classes are combined [<a href="#rid99">99</a>]. As use of these agents increases, there are more cases of patients developing autoimmune retinopathy.</p><p>With all checkpoint inhibitors, concerns for autoimmune disease (including myasthenia gravis), thyroid eye disease, uveitis (including punctate inner choroidopathy/multifocal choroiditis, also called white dot syndrome or birdshot-like chorioretinopathy [<a href="#rid100">100</a>]), and exacerbation of paraneoplastic syndromes (including melanoma-associated retinopathy) need to be considered.</p><p>For patients receiving the anti-PD-1 antibodies <a class="drug drug_general" data-topicid="98764" href="/d/drug information/98764.html" rel="external">nivolumab</a> or <a class="drug drug_general" data-topicid="119172" href="/d/drug information/119172.html" rel="external">cemiplimab</a>, if uveitis occurs in combination with other immune-mediated adverse reactions (eg, cutaneous [vitiligo, poliosis, alopecia], auditory [tinnitus], or neurologic [cerebrospinal fluid pleocytosis, meningismus]) [<a href="#rid101">101-103</a>], consider a VKH-like syndrome, which has been observed in patients treated with cemiplimab alone, nivolumab alone, or nivolumab in combination with <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a> and may require treatment with systemic steroids to reduce the risk of permanent vision loss.</p><p class="headingAnchor" id="H239682581"><span class="h4">ASCO guidelines for counseling and management</span><span class="headingEndMark"> — </span>Specific guidelines for counseling patients about ocular side effects and which ocular symptoms should be reported to the health care provider, and recommendations for ophthalmology referral and management of uveitis/iritis and episcleritis in patients treated with immune checkpoint inhibitors are available from the ASCO  (<a class="graphic graphic_table graphicRef116764" href="/d/graphic/116764.html" rel="external">table 3</a>) [<a href="#rid104">104</a>].</p><p class="headingAnchor" id="H823406261"><span class="h3">Anaplastic lymphoma kinase inhibitors</span><span class="headingEndMark"> — </span>Visual disturbances have been seen in up to 65 percent of patients treated with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> in the phase II studies [<a href="#rid105">105,106</a>]. The main complaints are trailing lights, flashes, and brief image persistence, primarily associated with the transition from dark to light [<a href="#rid46">46,106-109</a>]. Uncommon visual manifestations included photophobia, decreased visual acuity, and blurred vision. Optic neuropathy and blindness have been reported, although they may have been related to prior whole-brain radiation therapy [<a href="#rid110">110</a>]. Across all clinical trials, the incidence of grade 4 visual field defect with vision loss was 0.2 percent (4 of 1719) [<a href="#rid111">111</a>].</p><p>Onset typically begins in the first week of starting <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>; symptoms tend to recur daily, last up to one minute, and generally have little to no impact on daily activity [<a href="#rid107">107</a>]. Similar symptoms have been reported with three other anaplastic lymphoma kinase inhibitors (<a class="drug drug_general" data-topicid="95046" href="/d/drug information/95046.html" rel="external">ceritinib</a>, <a class="drug drug_general" data-topicid="112993" href="/d/drug information/112993.html" rel="external">brigatinib</a>, and <a class="drug drug_general" data-topicid="119539" href="/d/drug information/119539.html" rel="external">lorlatinib</a>), but their overall incidence (all grade) is less than 15 percent.</p><p>The mechanism is unclear. Detailed ophthalmological assessment in over 200 patients from phase II experience with <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> did not demonstrate any objective abnormalities associated with visual symptoms [<a href="#rid112">112</a>].</p><p>No therapies are known to help. Symptoms often improve with length of time receiving therapy [<a href="#rid106">106</a>], and treatment cessation is usually not needed. The United States Prescribing Information for <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a> recommends discontinuation of the drug in patients with new onset of severe visual loss (best corrected vision less than 20/200 in one or both eyes). The decision to resume therapy must be individualized, weighing the risks of visual loss with the potential benefits of treatment discontinuation to the patient. The United States Prescribing Information for <a class="drug drug_general" data-topicid="112993" href="/d/drug information/112993.html" rel="external">brigatinib</a> recommends withholding the drug for grade 2 (symptomatic, with moderate decrease in visual acuity [no worse than 20/40]; limiting instrumental activities of daily living [ADL]) or grade 3 (symptomatic, with marked decrease in visual acuity [worse than 20/40 but not 20/200]; disabling; limiting self-care ADL) visual loss until resolved to grade 1 (asymptomatic), and restarting at a reduced dose; they recommend permanent discontinuation for grade 4 visual loss (blindness [20/200 or worse] in the affected eye).</p><p class="headingAnchor" id="H4076373924"><span class="h3">Tamoxifen and toremifene</span><span class="headingEndMark"> — </span>The selective estrogen receptor modulators <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="10164" href="/d/drug information/10164.html" rel="external">toremifene</a> have been associated with asymptomatic corneal deposits [<a href="#rid113">113,114</a>]. A meta-analysis of three studies shows incidence is 0.7 percent for toremifene and 0.3 percent for tamoxifen [<a href="#rid115">115</a>]. Corneal pigmentation was reversible upon cessation of drug [<a href="#rid116">116,117</a>]. Continuation of therapy is likely safe if corneal deposits are found. Periodic follow-up with an ophthalmologist to monitor deposits is recommended. (See <a class="local">'Corneal deposits'</a> above.)</p><p>Cataracts have been reported in association with both drugs (3.7 percent for <a class="drug drug_general" data-topicid="10164" href="/d/drug information/10164.html" rel="external">toremifene</a> and 3.2 percent for <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> [<a href="#rid115">115</a>]). Surgical lens replacement is recommended when cataracts become visually significant. Since cataracts are well treated surgically, patients may not have to discontinue treatment because of this side effect. (See <a class="local">'Cataracts'</a> above.)</p><p><a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">Tamoxifen</a> was first reported to be associated with irreversible refractile retinal deposits in women taking high doses of the drug for metastatic breast cancer [<a href="#rid117">117</a>]. Subsequently, reports were also noted with tamoxifen given at standard doses for adjuvant therapy of breast cancer (20 mg daily), although this side effect appears to be rare [<a href="#rid118">118,119</a>]. Retinal deposits occur more often as total cumulative dose reaches 100 grams.</p><p>Macular edema is often associated with these deposits, which are typically located in the paramacular region [<a href="#rid120">120-125</a>]. Significant vision loss occurs in only a subset of these patients. Macular edema and vision loss may resolve with discontinuation of therapy, but the pigmentary changes and the retinal deposits persist. We recommend referral to a specialist to evaluate for evidence of refractile deposits or macular edema at any evidence of visual symptoms. Therapy may need to be discontinued as prolonged macular edema is likely damaging to the retina. No proven treatment for macular edema associated with <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> has been described besides cessation of tamoxifen itself. (See <a class="local">'Pigment changes, cotton wool spots, and hemorrhages'</a> above.)</p><p class="headingAnchor" id="H27978066"><span class="h3">Tyrosine kinase inhibitors</span><span class="headingEndMark"> — </span>Several ocular toxicities are reported with a variety of tyrosine kinase inhibitors (TKIs) targeting different receptors.</p><p class="headingAnchor" id="H202841797"><span class="h4">Imatinib</span><span class="headingEndMark"> — </span>The TKI with the greatest frequency of ocular side effects is <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>, which targets the KIT, Platelet-derived growth factor receptor (PDGFR), and BCR-ABL tyrosine kinases:</p><p class="bulletIndent1"><span class="glyph">●</span>Mild/moderate periorbital edema is a common side effect of <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> [<a href="#rid126">126</a>], shown to occur in 70 out of 147 (47.6 percent) patients taking imatinib in a phase II clinical trial for gastrointestinal stromal tumors [<a href="#rid127">127</a>]. Another retrospective review of imatinib (in clinical trials from a single center) showed 73 of 104 (70 percent) with periorbital edema [<a href="#rid128">128</a>]. Usually, conservative-management topical steroids and diuretics can control symptoms, and therapy doesn't need to be stopped. If symptoms are intolerable and therapy is stopped, rechallenge results in recurrence of symptoms in approximately one-half of patients [<a href="#rid128">128</a>]. Occasionally, dramatic periorbital edema impairs function [<a href="#rid129">129</a>] and requires surgical treatment. (See <a class="local">'Periorbital edema'</a> above.)</p><p></p><p class="bulletIndent1">Another major ocular complaint is epiphora [<a href="#rid126">126,128,130</a>], which has been attributed not to nasolacrimal duct obstruction but to poor lid apposition to the globe from periorbital edema and conjunctival chalasis [<a href="#rid130">130</a>]. Improvement typically occurs with cessation of therapy. (See <a class="local">'Epiphora and nasolacrimal duct obstruction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> has also been associated with spontaneous subconjunctival hemorrhage, which occurred in absence of systemic bleeding tendencies or bone marrow suppression. This occurred in 10 patients (11 percent) [<a href="#rid131">131</a>]. There was recurrence in six patients, but no other ocular sequelae ensued. Although aesthetically displeasing, this condition is benign, and cessation of treatment is not necessary. (See <a class="local">'Conjunctival hemorrhage'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">Imatinib</a> is associated with rare incidences of retinal hemorrhages in the first few months after starting treatment [<a href="#rid128">128,132-134</a>]. These are usually reversible. Cystoid macular edema and optic nerve edema have also been reported rarely [<a href="#rid135">135-139</a>]. Referral to a retina specialist is recommended. No effective treatments have been reported. Cessation of medication may be necessary in severe cases. (See <a class="local">'Retina'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rare cases of optic neuritis have been reported in association with <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> use [<a href="#rid135">135,138,140</a>]. Vision loss varied from mild to severe on initial presentation but eventually improved almost to baseline with cessation of therapy [<a href="#rid138">138,140</a>]. Discontinuing treatment should be considered. However, this decision must be individualized, taking into account the availability of an alternative therapy and the risks versus benefits of treatment discontinuation versus continuation. In one case, rechallenge was associated with worsening vision, but in another, rechallenge was well tolerated [<a href="#rid138">138,140</a>]. (See <a class="local">'Optic nerve'</a> above.)</p><p></p><p class="headingAnchor" id="H3872310958"><span class="h4">Vandetanib</span><span class="headingEndMark"> — </span>The multikinase inhibitor <a class="drug drug_general" data-topicid="16484" href="/d/drug information/16484.html" rel="external">vandetanib</a>, which targets the EGFR, vascular endothelial growth factor receptor (VEGFR), and RET and SRC kinases, has been reported to cause corneal verticillata (deposits) [<a href="#rid11">11,28,141</a>]. Incidence is rare, and symptoms are generally mild. Blurriness and glare have been managed symptomatically with <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>. One case reported that dose reduction improved symptoms, but corneal findings persisted. Follow-up with an ophthalmologist is recommended to monitor the corneal findings, but given the mild effects on vision, cessation of treatment is not usually necessary.</p><p class="headingAnchor" id="H3715823322"><span class="h4">Nilotinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">Nilotinib</a> is a selective TKI that targets BCR-ABL, KIT, and PDGFR. It was associated with mild dry eye symptoms in three out of nine patients in a phase II clinical trial [<a href="#rid142">142</a>]. Nilotinib has also been associated with a case of xanthomas of the eyelids, but these were probably related to systemic elevation of cholesterol, which seemed to be "unmasked" by the initiation of nilotinib [<a href="#rid143">143</a>]. These lesions are benign but should alert the clinician to the need for a systemic workup.</p><p class="headingAnchor" id="H299513117"><span class="h3">Ponatinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="87456" href="/d/drug information/87456.html" rel="external">Ponatinib</a> is a third generation TKI that targets BCR-ABL, and several other receptors, including FGFR. Ocular toxicities are reported in 30 percent of patients receiving the drug for refractory CML, but the specific molecular target responsible for these toxicities is not established. Ocular toxicity from this agent is described in more detail above. (See <a class="local">'Fibroblast growth factor receptor (FGFR) inhibitors'</a> above.)</p><p class="headingAnchor" id="H3872235854"><span class="h4">Sorafenib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">Sorafenib</a> is a multitargeted TKI that targets KIT, PDGFR, and VEGFR-1, 2, and 3. It has been associated with the development of squamoproliferative lesions, such as keratoacanthomas and squamous cell carcinomas, that can affect the eyelid. The risk and natural history are not well defined.</p><p>Squamoproliferative lesions that develop during <a class="drug drug_general" data-topicid="10277" href="/d/drug information/10277.html" rel="external">sorafenib</a> therapy should be treated similarly to lesions that develop in patients not receiving the drug (usually with complete surgical excision). However, spontaneous regression of keratoacanthomas has been reported after discontinuation of the drug and also in a few patients who continued therapy. Definitive guidelines for continuing versus discontinuing sorafenib in patients who develop squamous cell carcinoma or keratoacanthomas while on therapy have not been established. Close clinical follow-up during treatment is warranted. (See  <a class="medical medical_review" href="/d/html/2088.html" rel="external">"Cutaneous adverse events of molecularly targeted therapy and other biologic agents used for cancer therapy", section on 'Squamoproliferative lesions'</a>.)</p><p class="headingAnchor" id="H979274408"><span class="h4">Pexidartinib</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="122066" href="/d/drug information/122066.html" rel="external">Pexidartinib</a> is an oral kinase inhibitor that targets colony stimulating factor 1 receptor (CSF1R); it is approved for advanced tenosynovial giant cell tumor. (See  <a class="medical medical_review" href="/d/html/7733.html" rel="external">"Treatment for tenosynovial giant cell tumor and other benign neoplasms affecting soft tissue and bone"</a>.)</p><p>Eye edema (including periorbital edema, eye edema, and eyelid edema) was reported in 30 percent of 61 patients treated with <a class="drug drug_general" data-topicid="122066" href="/d/drug information/122066.html" rel="external">pexidartinib</a> in one trial; it was severe (grade 3 or worse) in 1.6 percent [<a href="#rid144">144</a>].</p><p class="headingAnchor" id="H1837955362"><span class="h4">Bruton tyrosine kinase inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="91587" href="/d/drug information/91587.html" rel="external">Ibrutinib</a> is a Bruton tyrosine kinase (BTK) inhibitor used for the treatment of hematologic malignancies. Several ophthalmic side effects have been reported, including blurred vision, dry eye, increased lacrimation, and uveitis [<a href="#rid145">145,146</a>]. Ocular side effects have not been reported in patients treated with a second BTK inhibitor, <a class="drug drug_general" data-topicid="115440" href="/d/drug information/115440.html" rel="external">acalabrutinib</a>.</p><p class="headingAnchor" id="H1282997041"><span class="h3">Antibody-drug conjugates</span><span class="headingEndMark"> — </span>Antibody-drug conjugates can be very toxic to the cornea. Many trials and prescribing information prohibit contact lens wearers from wearing their contact lenses during therapy because of concerns that the antibody drug might get into high concentration in the contact lens and exacerbate drug-related corneal toxicity.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Belantamab mafodotin</strong> – <a class="drug drug_general" data-topicid="129194" href="/d/drug information/129194.html" rel="external">Belantamab mafodotin</a> is an anti-B-cell maturation antigen humanized immunoglobulin G antibody conjugated to the microtubular disrupting agent monomethyl auristatin; it had been approved for relapsed and refractory multiple myeloma, but was voluntarily withdrawn from the United States market in December 2022 because of treatment inefficacy in clinical trials. It remains available on a compassionate use basis for patients already receiving the drug at the time of the withdrawal.</p><p></p><p class="bulletIndent1">In a pooled safety population of 218 patients who received the drug, corneal epithelial changes (keratopathy) were the most common toxicity, occurring in 76 percent of patients, the majority of whom had clinically relevant visual acuity changes [<a href="#rid147">147</a>]. The keratopathy was grade 1 or 2 in 29 percent, and grade 3 or 4 in 46 percent. Corneal ulcers were reported. The majority developed during the first two treatment cycles. Other ocular adverse reactions included blurred vision (27 percent) and dry eye (19 percent). Most cases of ocular toxicity reversed with dose reduction or delay, and the use of <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>. A similar conclusion was reached in a retrospective analysis of 56 patients receiving <a class="drug drug_general" data-topicid="129194" href="/d/drug information/129194.html" rel="external">belantamab mafodotin</a> for relapsed/refractory myeloma [<a href="#rid148">148</a>]; corneal toxicity was milder among patients who restarted the drug at a lower dose after temporary treatment discontinuation.</p><p></p><p class="bulletIndent1">The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3D16a160a4-3ec0-4ddf-99ce-05912dd3382d&amp;token=FapdyfAODAZJcUir8nRs7J0cdR46LRSBnElKOINt8%2FGvADtAtEiUyw25jWdQqQ2PnOY%2BZYbDtHvpPE4Jak2de9lAsLJhMrdJfNfdpVA34%2BjNH88dVKyd0MuyQNzi7dC0&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for belantamab mafodotin</a> advises an ophthalmologic examination (visual acuity and slit-lamp) at baseline, prior to each dose, and promptly for worsening symptoms. Patients should use a lubricant eye drop at least four times daily starting with the first infusion, and continuing until the end of treatment. Ophthalmic topical corticosteroids are often helpful; in our experience, topical (ophthalmic) <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a> is not. Contact lenses should be avoided during treatment unless directed by an ophthalmologist. Recommendations for dose modification based on corneal toxicity are provided.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">Enfortumab vedotin</a> – Enfortumab vedotin is a nectin-4-directed antibody microtubule inhibitor drug conjugate that is approved for metastatic refractory urothelial cancer. (See  <a class="medical medical_review" href="/d/html/3000.html" rel="external">"Treatment of metastatic urothelial carcinoma of the bladder and urinary tract", section on 'Enfortumab vedotin'</a>.)</p><p></p><p class="bulletIndent1">In the initial clinical trial, involving 125 patients treated with <a class="drug drug_general" data-topicid="126407" href="/d/drug information/126407.html" rel="external">enfortumab vedotin</a>, ocular disorders included dry eye in 29 (23 percent), blurred vision in 19 (15 percent), and increased lacrimation in 18 (14 percent) [<a href="#rid149">149</a>]. In an analysis of 310 patients treated with the drug, ocular disorders occurred in 46 percent, and the majority involved the cornea, including keratitis, blurred vision, limbal stem cell deficiency, and other events associated with dry eye [<a href="#rid150">150</a>].</p><p></p><p class="bulletIndent1">The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2019%2F761137s000lbl.pdf&amp;token=s8biZVEkXw5A5V82SutkU8%2FhggB4UAeaUP3t5Pe3aQ8woxCoTlVu0yhAlTNp5xFzJ8gfhltUyxq5Ik0RPR%2F1c92a%2BDEra90bCmwk3ceTiA4%3D&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for enfortumab vedotin</a> recommends <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> for prophylaxis of dry eyes, and ophthalmologic evaluation if ocular symptoms occur or do not resolve. Options for symptomatic ocular disorders include ophthalmic topical steroids, dose interruption, or dose reduction. In our experience, ophthalmic topical cyclosporin is not helpful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="132755" href="/d/drug information/132755.html" rel="external">Tisotumab vedotin</a> – Tisotumab vedotin is a tissue factor-directed antibody and microtubule inhibitor drug-conjugate approved for use for those with recurrent or metastatic cervical cancer with disease progression on, or after, chemotherapy. (See  <a class="medical medical_review" href="/d/html/3185.html" rel="external">"Management of recurrent or metastatic cervical cancer", section on 'Second-line therapy'</a>.)</p><p></p><p class="bulletIndent1">In a study in 101 patients receiving <a class="drug drug_general" data-topicid="132755" href="/d/drug information/132755.html" rel="external">tisotumab vedotin</a>, eye disorders included conjunctival adverse reactions in 37 percent (conjunctivitis, conjunctival abrasion, erosion, hyperemia, scar, or hemorrhage), dry eye or increased lacrimation (29 percent), corneal adverse reactions in 21 percent (keratitis, keratopathy, corneal erosions, and corneal bleeding), and periorbital adverse reactions in 16 percent (blepharitis, meibomianitis, eye pruritus, entropion, trichiasis, chalazion, and meibomian gland dysfunction) [<a href="#rid151">151</a>]. Three percent had grade 3 to 4 corneal adverse reactions [<a href="#rid151">151</a>].</p><p></p><p class="bulletIndent1">The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2021%2F761208Orig1s000lbledt.pdf&amp;token=LdXdZvbTOHxq%2FF1yqOzoNJhLHfMCZ8w0%2BHcgoU6brKtBtIPFLJIaS%2B13nyHoN8UMbBsaYGLfVNFrXrcunPUEKZ6x4hRSyF1Z%2BvyKb8yRtiygwBjDEr%2BtbWwOa02xSDpX&amp;TOPIC_ID=96203" target="_blank">United States Prescribing Information for tisotumab vedotin</a> advises an ophthalmic examination (including visual acuity and slit lamp examination) at baseline, prior to each dose, and as clinically indicated. All patients should receive topical corticosteroid and vasoconstrictor eye drops prior to each dose, and use eye cooling pads during drug infusion. In addition, patients should administer lubricating eye drops for the duration of therapy, and 30 days after treatment discontinuation. Patients should avoid wearing contact lenses during treatment, unless directed by an ophthalmologist. Dose modification guidelines based on the severity of ocular toxicity are provided.</p><p></p><p class="headingAnchor" id="H27978194"><span class="h2">Traditional chemotherapy agents</span></p><p class="headingAnchor" id="H871036471"><span class="h3">Bortezomib and eyelid disorders</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">Bortezomib</a>, a proteasome inhibitor, is associated with case reports of severe meibomian gland disease and development of chalazia on multiple lids [<a href="#rid152">152-154</a>]. Several were severe enough to prompt discontinuation of bortezomib or at least temporary withholding of the drug. Rechallenge resulted in recurrence of chalazia for the majority of patients [<a href="#rid152">152</a>]. Management of bortezomib-induced chalazia is relatively unsatisfactory with standard treatment regimens, which include warm compresses, lid hygiene, topical and oral antibiotics [<a href="#rid152">152,155</a>] and steroids, and surgical incision and drainage. Patients present with multiple chalazia on the upper and lower lids, and traditional medical management is only minimally effective. Surgical treatment may be impractical due to the multiplicity of lesions and the increased risk of scarring and lid malposition. There is a high rate of recurrence. In general, symptoms are reversible on discontinuation of the drug. (See <a class="local">'Blepharitis and meibomian gland dysfunction'</a> above and <a class="local">'Chalazia and other eyelid masses'</a> above.)</p><p>Ultimately, the decision to stop or continue <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a> must be individualized. The benefits of continuing the drug (versus switching to an alternative potentially effective therapy) must be weighed against the risks and consequences of ongoing ocular toxicity. Optimally, this decision should be made jointly by the patient, the oncologist, and the ophthalmologist. Notably, chalazia and meibomian gland dysfunction have not been reported with the second-generation proteasome inhibitor <a class="drug drug_general" data-topicid="86042" href="/d/drug information/86042.html" rel="external">carfilzomib</a>.</p><p class="headingAnchor" id="H3319756043"><span class="h3">Taxanes</span></p><p class="headingAnchor" id="H656342024"><span class="h4">Epiphora and docetaxel</span><span class="headingEndMark"> — </span>Excess tearing (epiphora) is reported in 21 to 86 percent of patients who receive <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> for metastatic cancer or in the adjuvant setting for treatment of early breast cancer [<a href="#rid156">156-159</a>]; some, but not all, of these patients have obstruction of the nasolacrimal system. Longer duration of therapy and higher cumulative doses are associated with worse disease severity. Weekly dosing is also associated with a higher frequency and severity of epiphora and with a higher risk for obstruction of the nasolacrimal system than every-three-week dosing [<a href="#rid157">157,160,161</a>]. In one study, while 30 out of 71 patients who developed epiphora with weekly dosing required surgery for obstruction of the nasolacrimal system, only 3 out of 71 of those who developed epiphora with every-two-to-three-week dosing required surgery [<a href="#rid162">162</a>]. Surgery in the weekly dosing group also tended to be more complicated. Patients who develop epiphora while receiving weekly therapy also tend to resolve less rapidly after treatment discontinuation [<a href="#rid160">160,161</a>]. (See <a class="local">'Epiphora and nasolacrimal duct obstruction'</a> above.)</p><p>Given the potential for severe, symptomatic, and irreversible obstruction of the nasolacrimal system over time [<a href="#rid163">163</a>], we recommend referral to a lacrimal specialist for evaluation and possible early preventive treatment for all patients who develop epiphora during <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> treatment. There may be benefit for early temporary silicone intubation for patients with progressive canalicular stenosis, to prevent permanent complete closure of the canaliculi and the need for much more involved surgery, and worse outcomes [<a href="#rid13">13,162</a>].</p><p class="headingAnchor" id="H3767711225"><span class="h4">Visual changes</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">Paclitaxel</a> is associated with transient scintillating scotomas during infusion in approximately 20 percent of patients [<a href="#rid118">118,164-166</a>]. These symptoms last approximately 15 minutes to 3 hours and occur mostly at the end of the infusion [<a href="#rid165">165,167</a>]. This was associated with visual-evoked potential changes [<a href="#rid164">164,166</a>], suggesting abnormalities in the optic nerve pathway. The mechanism of these changes is unclear, but the hypothesis is either transient ischemia or neurotoxic effects of taxanes. (See <a class="local">'Optic nerve'</a> above.)</p><p><a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">Docetaxel</a> has been associated with a rare case of toxic optic neuropathy, causing constriction of visual fields, loss of visual acuity, and loss of color vision [<a href="#rid168">168</a>]. Optic nerve edema and disc hemorrhages were present, and complete lab work and imaging was otherwise negative. Treatment with intravenous corticosteroids with oral taper was used. Vision and visual fields gradually improved over three months. (See <a class="local">'Optic nerve'</a> above.)</p><p>While the scintillating scotomas reported with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> are a mild, non-vision-threatening, reversible condition, prolonged optic nerve edema is potentially vision threatening and, at least in the one case, was reversible upon cessation of therapy. There is not sufficient evidence to say whether corticosteroids help or whether cessation of therapy is enough. Referral to a neuro-ophthalmologist is recommended with repetitive instances of scotomas and promptly with vision loss.</p><p class="headingAnchor" id="H3854437657"><span class="h4">Cystoid macular edema</span><span class="headingEndMark"> — </span>There are case reports of mild/moderate bilateral cystoid macular edema without evidence of leakage on retinal imaging both with <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> and <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid169">169-173</a>]. Edema resolved with cessation of therapy [<a href="#rid170">170,172,174</a>]. <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">Acetazolamide</a> has been used and reported in a few cases to help with edema [<a href="#rid169">169,173</a>].</p><p>For patients with a viable alternative to the use of a taxane, we recommend discontinuation of the taxane and referral to a retina specialist to manage the ocular findings. If no effective treatment alternative exists, the benefits of continuing the taxane must be weighed against the risks and consequences of ongoing ocular toxicity. Optimally, this decision should be made jointly by the patient, the oncologist, and the ophthalmologist. (See <a class="local">'Macular edema, central serous retinopathy, and serous retinal detachment'</a> above.)</p><p class="headingAnchor" id="H2418438439"><span class="h3">Fluoropyrimidines</span><span class="headingEndMark"> — </span>Fluoropyrimidines are used widely for a variety of different cancers, and their use is frequently associated with ocular side effects:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">Fluorouracil</a> (FU) is commonly associated with excess tearing (30 to 50 percent [<a href="#rid175">175-177</a>]). The causes are multifactorial, including ocular surface disease, dry eyes, and canalicular stenosis or obstruction of the nasolacrimal system [<a href="#rid175">175-185</a>]. Canalicular stenosis is reported in 4 to 15 percent of treated patients [<a href="#rid175">175,177,178</a>], and this has required canalicular stenting with silastic tubing, dacryocystorhinostomy, or occasionally, conjunctivodacryocystorhinostomy [<a href="#rid179">179,181,182,184</a>]. (See <a class="local">'Epiphora and nasolacrimal duct obstruction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>FU-induced eyelid dermatitis and lid margin inflammation can lead to cicatricial changes that cause poor apposition of the lids (eyelid ectropion 1.9 percent) [<a href="#rid175">175,183</a>] and eyelid margin fusion [<a href="#rid180">180</a>], leading to evaporative dry eye and reflexive tearing. (See <a class="local">'Cicatricial eyelid changes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other reported ocular toxicities from FU-based therapies include eyelid conjunctival hyperemia (39.4 percent), lid margin abnormalities (41 percent), corneal punctate epithelial erosions (3.2 percent), and lower eyelid punctal edema (5 percent) [<a href="#rid175">175,178</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overall, the high rate of burning, tearing, and ocular irritation seen with FU-based therapies [<a href="#rid176">176,186</a>] is likely related to dry eye caused by toxicities to the cornea, conjunctiva, and eyelid, all of which contribute to a healthy tear film.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The oral fluoropyrimidine <a class="drug drug_general" data-topicid="8839" href="/d/drug information/8839.html" rel="external">capecitabine</a> has been associated with two cases of corneal deposits with mild blurriness of vision [<a href="#rid15">15</a>]. These deposits resolved with discontinuation of drug, and rechallenge led to recurrence. (See <a class="local">'Corneal deposits'</a> above.)</p><p></p><p>We recommend referral to an ophthalmologist and/or switching to an alternative agent if symptoms are not relieved by conservative management with lubrication (<a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a>) or if there is evidence of obstruction of the nasolacrimal system. Though no data have shown prevention of extensive stenosis with early stenting in patients treated with FU, early stenting of nasolacrimal system obstruction related to <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> chemotherapy has prevented far more invasive nasolacrimal surgery. (See <a class="local">'Taxanes'</a> above.)</p><p class="headingAnchor" id="H27978210"><span class="h3">Busulfan and cataracts</span><span class="headingEndMark"> — </span>The alkylating agent <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a> has been associated with the development of cataracts in the pediatric population when used as part of treatment for leukemia. The reported incidence is around 10 of 79 (12.7 percent) in a meta-analysis [<a href="#rid187">187</a>] and 12.5 percent in another study [<a href="#rid188">188</a>]. The visual significance of these cataracts is not as well described. They appear to be posterior subcapsular cataracts, and in one study, out of five children who developed cataracts in association with busulfan, one needed cataract surgery [<a href="#rid189">189</a>]. The time to formation of cataracts ranged from one to seven years [<a href="#rid189">189</a>]. Cataracts in the pediatric population need individualized treatment. The decision for surgical extraction of the lens depends on a variety of factors, including the visual significance of the cataract, the age of the patient, the risks for amblyopia if left untreated, the inflammatory reaction and difficult postoperative care in a child, and the changing refraction of the eye during growth, amongst other factors. As cataracts likely develop post-treatment, we recommend referral to an ophthalmologist at any sign of difficulty with vision (which, in a child, can present as difficulty with schoolwork or preference for one eye over the other).</p><p class="headingAnchor" id="H27978222"><span class="h3">Cytarabine and fludarabine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a> has been associated with corneal deposits that are dose dependent, with high incidences when dosing reaches 3 g/m<sup>2</sup> but minimal at 1 to 2 g/m<sup>2</sup> [<a href="#rid190">190,191</a>]. Patients complain of conjunctival injection, photophobia, foreign body sensation, and mild to moderate vision loss. Incidence can be as high as 85 percent [<a href="#rid192">192</a>]. On slit lamp examination, corneal epithelial microcysts are noted. (See <a class="local">'Corneal deposits'</a> above.)</p><p>Symptoms and corneal findings are reversible with cessation of treatment, and vision usually returns back to baseline [<a href="#rid193">193,194</a>]. <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">Prednisolone</a> eye drops can help with symptomatic management, although benefit has not been shown in all studies. One study found no difference in grade 2/3 symptoms with or without prednisolone eye drops [<a href="#rid191">191</a>]. Topical 2-deoxycytidine, a competitive inhibitor of <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a>, was equally effective as topical prednisolone in a small, double-masked, randomized study of 11 patients [<a href="#rid195">195</a>]. Ophthalmologic referral is recommended.</p><p>Rare case reports of anterior uveitis have occurred when <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> was used as single agent [<a href="#rid196">196</a>], in combination in hyper-CVAD protocol (<a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> alternating with <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> and high-dose arabinoside) [<a href="#rid197">197</a>], or in combination with gemtuzumab [<a href="#rid9">9</a>]. Anterior uveitis resolved within a few days of treatment with topical steroids and mydriatics. We recommend prompt referral to an ophthalmologist at signs and symptoms of uveitis for treatment to prevent vision loss or future ocular complications. (See <a class="local">'Uveitis and ocular inflammation'</a> above.)</p><p>High-dose <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> used in the setting of induction for hematopoietic cell transplantation in conjunction with total-body irradiation has been uncommonly associated with retinal microvascular damage, including capillary nonperfusion and subsequent sequelae, such as neovascularization, vitreous hemorrhage, and macular edema [<a href="#rid198">198</a>]. It has been suggested that ocular damage in these patients may be a consequence of the radiosensitizing potential of cytarabine [<a href="#rid198">198</a>]. In one case report, complications from retinal ischemia eventually led to tractional retinal detachment involving the macula, with poor visual prognosis [<a href="#rid199">199</a>]. We recommend referral to a retina specialist if there is any evidence of vision loss in order to coordinate care. Retinal imaging may better define severity of retinal nonperfusion and need/benefit from local management versus cessation of therapy. (See <a class="local">'Macular edema, central serous retinopathy, and serous retinal detachment'</a> above.)</p><p><a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">Fludarabine</a> has been associated with rapid vision loss in three cases in the literature, all when fludarabine was administered prior to hematopoietic cell transplantation [<a href="#rid200">200</a>]. Fundus examination showed punctate yellow flecks in the macula, and histology showed loss of retinal bipolar and ganglion cells. There is not enough evidence about reversibility to make specific recommendations. However, early referral to a retina specialist is advised. (See <a class="local">'Pigment changes, cotton wool spots, and hemorrhages'</a> above.)</p><p class="headingAnchor" id="H3952565009"><span class="h3">Pentostatin, methotrexate, and pemetrexed</span><span class="headingEndMark"> — </span>The antimetabolite <a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">pentostatin</a> has been associated with keratitis, in which there are<strong><em> </em></strong>corneal dendritic ulcerations of similar morphology to herpes simplex keratitis (affecting 3 out of 15 patients in one study [<a href="#rid201">201</a>]). These lesions, however, occurred bilaterally and were associated with pain, whereas herpes keratitis doesn't usually occur simultaneously in both eyes unless the patient is immunocompromised. Decreased corneal sensation is also typical of herpetic keratitis. (See  <a class="medical medical_review" href="/d/html/6896.html" rel="external">"Herpes simplex keratitis"</a>.)</p><p>Pain and photophobia may persist for several days. If a patient presents with these clinical findings, we recommend prompt referral to an ophthalmologist to help distinguish the etiology. Symptomatic management with <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">artificial tears</a> has been successful. In the case series discussed above, corneal healing was complete in 14 to 21 days [<a href="#rid201">201</a>]. (See <a class="local">'Corneal epithelial defects'</a> above.)</p><p><a class="drug drug_general" data-topicid="9756" href="/d/drug information/9756.html" rel="external">Pentostatin</a> has also been associated with conjunctivitis, keratoconjunctivitis, and periorbital edema [<a href="#rid202">202-206</a>]. Patients may complain of ocular pain, photophobia, burning, and itching. Treatment is usually supportive, but discontinuation of therapy may be necessary [<a href="#rid207">207</a>].</p><p>Therapy with high-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> (as is used for central nervous system lymphoma and osteosarcoma treatment) is rarely associated with ocular anterior surface irritation two to seven days after starting therapy [<a href="#rid208">208</a>]. Symptoms are usually mild and not vision threatening. (See  <a class="medical medical_review" href="/d/html/1155.html" rel="external">"Therapeutic use and toxicity of high-dose methotrexate"</a>.)</p><p class="headingAnchor" id="H4169728676"><span class="h4">Low-dose methotrexate and optic neuropathy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">Methotrexate</a> is rarely associated with toxic posterior optic neuropathy. Visual field scotomas, optic nerve edema, and optic atrophy have all been reported [<a href="#rid209">209-212</a>], predominantly after longstanding treatment with low-dose methotrexate, with or without <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> supplementation, in the treatment of rheumatologic diseases. Recovery of vision did occur in a few cases after discontinuation of methotrexate [<a href="#rid210">210,212</a>]. We recommend cessation of therapy at the first evidence of vision loss and referral to a specialist for further management. (See  <a class="medical medical_review" href="/d/html/7509.html" rel="external">"Major side effects of low-dose methotrexate", section on 'Others'</a>.)</p><p>The optic neuropathy seen in patients treated with low-dose <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a> has been linked to folate deficiency, either nutritional or genetic [<a href="#rid210">210</a>]. Folate supplementation, when co-administered with methotrexate, minimizes its adverse effects [<a href="#rid213">213</a>] and may, therefore, prevent the development of optic neuropathy. In addition, when this condition is recognized, the nerve damage may be reversible if methotrexate is stopped and if appropriate folate supplementation is administered promptly [<a href="#rid210">210</a>].</p><p class="headingAnchor" id="H413362986"><span class="h4">Pemetrexed and eye edema</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">Pemetrexed</a>, a <a class="drug drug_general" data-topicid="8475" href="/d/drug information/8475.html" rel="external">folic acid</a> antagonist, has been associated with lower eyelid edema, although the true incidence is difficult to ascertain. The May 2008 version of the Pemetrexed Clinical Investigator's Brochure suggested an incidence of 0.4 percent (6 cases out of 1364 treated patients) [<a href="#rid214">214</a>]. However, the frequency of eyelid edema was 2.3 percent in a phase II clinical study of pemetrexed with concomitant <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> or <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> [<a href="#rid214">214</a>]. The eyelid edema was attributed to pemetrexed because it was reversed after stopping pemetrexed but not carboplatin. Eyelid edema has not been associated with systemic fluid retention [<a href="#rid214">214,215</a>]. (See <a class="local">'Orbit and periorbital tissue'</a> above.)</p><p>Others report a higher frequency of adverse effects affecting the eye in patients treated with <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>. In a review of 107 patients treated with four or more cycles of pemetrexed [<a href="#rid216">216</a>], periorbital edema (not just limited to the lower eyelid) developed in 16 (15 percent). In this series, the most common cutaneous adverse event was drug-induced conjunctivitis in 27 (26 percent), which seemed to precede an inflammatory edema of the eyelid.</p><p>Rechallenge has led to worsening eyelid edema in one case report [<a href="#rid217">217</a>]. Chronic edema can potentially lead to lower lid laxity or cicatricial changes in the future, but given the reversibility of the condition and the generally non-vision-threatening nature of the side effect, it is likely safe to continue treatment of the malignancy, particularly if there are no other viable treatment alternatives. <a class="drug drug_general" data-topicid="8660" href="/d/drug information/8660.html" rel="external">Artificial tears</a> could be added to prevent any evaporative dry eye caused by lower lid sagging.</p><p class="headingAnchor" id="H27978228"><span class="h3">Anthracyclines and anthracenediones</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9391" href="/d/drug information/9391.html" rel="external">Doxorubicin</a> and <a class="drug drug_general" data-topicid="8663" href="/d/drug information/8663.html" rel="external">epirubicin</a> have been associated with conjunctivitis [<a href="#rid218">218,219</a>], especially following accidental ocular exposure. The incidence is 25 percent in conjunction with <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid220">220</a>] and 39 percent in conjunction with <a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a> [<a href="#rid178">178</a>]. The vast majority of chemical conjunctivitis cases resolved within a day after exposure [<a href="#rid218">218</a>]. Cautious rechallenge of therapy is probably reasonable as toxicity resolves quickly and is not vision threatening. (See <a class="local">'Conjunctivitis'</a> above.)</p><p>Mild/moderate chemical conjunctivitis was also reported in 6 percent of patients treated with combination <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> and <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a> for refractory non-Hodgkin lymphoma [<a href="#rid221">221</a>]. As cytarabine can also sometimes present with conjunctival injection, it is unclear whether cytarabine has a contribution to the reactions seen or whether there is a synergistic effect when both are taken together.</p><p>In general, conjunctivitis can be managed conservatively, and therapy likely does not have to be withdrawn. (See <a class="local">'Conjunctivitis'</a> above.)</p><p><a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">Mitoxantrone</a> has been associated with secondary acute promyelocytic leukemia [<a href="#rid222">222,223</a>]. In at least one report, this manifested as optic nerve infiltration by leukemia cells [<a href="#rid224">224</a>]. This rare occurrence should be considered if a patient presents with optic nerve abnormalities on examination while receiving mitoxantrone. (See <a class="local">'Optic nerve'</a> above.)</p><p class="headingAnchor" id="H4015849342"><span class="h3">Interferon</span><span class="headingEndMark"> — </span>Interferons are associated with several ocular side effects; mostly these have been reported in patients receiving interferon alfa 2b, which was withdrawn from the global market in 2021. There are only scattered reports of these toxicities in patients receiving interferon alfa 2a.</p><p class="bulletIndent1"><span class="glyph">●</span>Both pegylated and nonpegylated <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> have been associated with development of uveitis when used in the treatment of hepatitis C viral infection [<a href="#rid225">225-228</a>]. Severe bilateral panuveitis with exudative retinal detachments has been reported, along with systemic manifestations of VKH (vertigo, skin/hair changes, hearing loss, and meningitis). Incidence is rare, but the condition is vision threatening. Prompt systemic corticosteroids and topical corticosteroid drops with prolonged taper have been tried with generally good response and control of uveitis [<a href="#rid225">225-227</a>]. Visual prognosis is uncertain and depends on the extent of ocular involvement. Referral to an ophthalmologist and a rheumatologist is recommended. (See <a class="local">'Uveitis and ocular inflammation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">Interferon alfa-2b</a> has been associated with trichomegaly of the eyelashes (irregular, elongated eyelash growth) [<a href="#rid229">229-235</a>]. No corneal decompensation has been reported. This uncommon side effect is mild and reversible after discontinuation of therapy, usually in approximately three months. (See <a class="local">'Trichiasis and trichomegaly'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">Interferon alfa-2b</a> has been associated with ischemic retinopathy. On funduscopic examination, intraretinal hemorrhages and cotton wool spots are seen. These findings are most commonly described in the chronic hepatitis C literature, but they are also reported in the treatment of cancer [<a href="#rid236">236-239</a>]. Close monitoring is recommended. Incidence of vision loss varies from 15 to 86 percent [<a href="#rid240">240-246</a>]. Most cases were mild and reversible, but vision loss can be severe. Serious side effects of retinal artery and vein occlusions have been reported [<a href="#rid238">238,247,248</a>]. <a class="drug drug_general" data-topicid="8461" href="/d/drug information/8461.html" rel="external">Fluorescein</a> angiography has shown poor perfusion of the retina [<a href="#rid239">239,249</a>]. Treatment should be stopped, and referral to a retina specialist is recommended. (See <a class="local">'Retina'</a> above.)</p><p></p><p class="bulletIndent1">Retinal toxicity is also reported in patients receiving pegylated interferon alfa 2a [<a href="#rid250">250</a>]. However, the risk seems relatively low, and treatment discontinuation is rarely necessary [<a href="#rid251">251</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Just as <a class="drug drug_general" data-topicid="8563" href="/d/drug information/8563.html" rel="external">interferon alfa-2b</a> can cause ischemia to the retina, it is also associated with reports of anterior ischemic optic neuropathy. Vision loss varies from mild, nonprogressive, or reversible vision loss after cessation of therapy and starting systemic steroids [<a href="#rid252">252-254</a>] to significant loss of visual acuity and loss of peripheral visual field that is irreversible even with steroid treatment [<a href="#rid252">252,255-258</a>]. Acutely, optic nerve head swelling, an afferent pupillary defect, and color vision loss are seen. Over time, optic atrophy with optic nerve head pallor can be seen. Nonarteritic ischemic optic neuropathy has also been rarely reported [<a href="#rid259">259,260</a>] with permanent altitudinal visual field loss and moderate central visual acuity loss. A significant number of subclinical abnormalities can be seen with visual-evoked potential testing. In a prospective study, visual-evoked response was abnormal in 15 out of 74 eyes (20.3 percent). Two-thirds were reversible after stopping interferon; one-third persisted but were clinically asymptomatic [<a href="#rid261">261</a>]. (See <a class="local">'Optic nerve'</a> above.)</p><p></p><p class="bulletIndent1">Optic neuropathy is also rarely reported in patients receiving interferon alfa 2a [<a href="#rid262">262</a>].</p><p></p><p class="bulletIndent1">It is unclear what population of people will get optic neuropathy from interferon treatment and who will have severe versus mild vision loss. Incidence is infrequent, but patients should be aware of the potential for significant vision loss. Referral to a neuro-ophthalmologist is recommended in the event of visual effects. Systemic corticosteroids are an option. (See  <a class="medical medical_review" href="/d/html/5234.html" rel="external">"Nonarteritic anterior ischemic optic neuropathy: Prognosis and treatment"</a>.)</p><p></p><p class="headingAnchor" id="H844285911"><span class="h3">Platinum analogs</span><span class="headingEndMark"> — </span>There are reports of retinal toxicity with <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid263">263,264</a>] and, to a lesser extent, with <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a> and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>. Ischemic retinopathy with cisplatin or carboplatin might be synergistic with coadministered <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a> [<a href="#rid265">265,266</a>]. Systemic administration of cisplatin with <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a> prior to hematopoietic cell transplantation has also been associated with retinal toxicity and vision loss, although it is not clear whether it was due to cisplatin or carmustine [<a href="#rid267">267</a>]. (See <a class="local">'Carmustine and retinal damage'</a> below.)</p><p>Additionally, the less severe side effects of granular pigmentary deposits and altered color vision have been described with both systemic and intra-arterial <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> [<a href="#rid268">268-272</a>]. Color vision changes can take months to years to return to baseline. It should be emphasized that these conditions are painless. (See <a class="local">'Pigment changes, cotton wool spots, and hemorrhages'</a> above.)</p><p><a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">Carboplatin</a> has been associated with rare case reports of optic nerve edema with hemorrhages and macular edema [<a href="#rid273">273,274</a>]. Irreversible vision loss and optic atrophy have resulted, even with cessation of therapy. Discontinuation of the drug should be considered at any signs of vision loss, and referral to a subspecialist should be made. (See <a class="local">'Optic nerve edema'</a> above.)</p><p><a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">Oxaliplatin</a> has been associated with rare cases of papilledema with intracranial hypertension [<a href="#rid275">275</a>]. Tunneling of vision was described. Treatment cessation and, in one case, initiation of oral <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> led to gradual improvement in optic disc swelling and improvement in vision. The recommended workup for these patients (which includes magnetic resonance imaging [MRI] of the head) is described above. (See <a class="local">'Optic nerve edema'</a> above.)</p><p>Referral to a neuro-ophthalmologist and close follow-up to monitor the condition of the optic nerve are recommended. Discontinuation of <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a> may be needed if unable to manage elevated intracranial hypertension. The decision to stop or continue oxaliplatin must be individualized. The benefits of continuing therapy (particularly where no effective treatment alternative exists) must be weighed against the risks and consequences of ongoing toxicity. Optimally, this decision should be made jointly by the patient, the oncologist, and the neuro-ophthalmologist.</p><p class="headingAnchor" id="H27978292"><span class="h3">Carmustine and retinal damage</span><span class="headingEndMark"> — </span>Intravenous <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a> in combination with high-dose <a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9308" href="/d/drug information/9308.html" rel="external">cyclophosphamide</a>, used in the setting of hematopoietic cell transplantation, has also been associated with severe cases of optic disc edema, pallor, and retinopathy [<a href="#rid267">267,276,277</a>], leading to irreversible optic nerve damage and vision loss. In a prospective trial of carmustine-based chemotherapy prior to hematopoietic cell transplantation, 25 percent of the patients developed retinal cotton wool spots or retinal hemorrhages [<a href="#rid278">278</a>]. In one case report, histopathology at autopsy showed patchy necrosis of the central nervous system and optic nerves consistent with small vessel thrombosis [<a href="#rid267">267,277</a>]. In most cases, drug administration has already been completed when the toxicity is discovered. If treatment is ongoing (for example, for systemic treatment of a brain tumor or Hodgkin lymphoma), discontinuation of therapy should be considered to prevent further potentially irreversible vision loss. Referral to and management by a retina specialist are recommended. (See <a class="local">'Pigment changes, cotton wool spots, and hemorrhages'</a> above.)</p><p class="headingAnchor" id="H1705986819"><span class="h3">Mitotane and retinopathy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">Mitotane</a> is used for the treatment of advanced adrenal cancer. (See  <a class="medical medical_review" href="/d/html/165.html" rel="external">"Treatment of adrenocortical carcinoma"</a>.)</p><p>At maximally tolerated doses of 8 to 10 g daily, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a> has uncommonly been associated with toxic retinopathy consisting of retinal hemorrhages, edema, and optic disc swelling (2 out of 139 and 3 out of 19 patients in two series [<a href="#rid279">279,280</a>]). Details on reversibility are unknown. We recommend referral to a specialist for evaluation and that consideration be given to stopping therapy if symptoms are severe and if the risks of ongoing therapy are thought to outweigh the benefits. (See <a class="local">'Pigment changes, cotton wool spots, and hemorrhages'</a> above and <a class="local">'Macular edema, central serous retinopathy, and serous retinal detachment'</a> above.)</p><p class="headingAnchor" id="H27978336"><span class="h3">All-trans retinoic acid</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9262" href="/d/drug information/9262.html" rel="external">All-trans retinoic acid</a> (tretinoin), which is used in the treatment of acute promyelocytic leukemia, is associated rarely with increased intracranial pressure and papilledema with splinter and flame hemorrhages [<a href="#rid281">281,282</a>]. Visual fields showed enlarged blind spots. Treatment with <a class="drug drug_general" data-topicid="9268" href="/d/drug information/9268.html" rel="external">acetazolamide</a> for increased intracranial pressure led to eventual resolution of papilledema. Final visual prognosis was good in the cases reported. Evaluation for and management of intracranial pathology are recommended in these cases. (See <a class="local">'Optic nerve edema'</a> above.)</p><p>Close follow-up with neuro-ophthalmology is recommended. Discontinuation of tretinoin may be needed if unable to manage elevated intracranial hypertension. The decision to stop or continue tretinoin must be individualized. The benefits of continuing tretinoin (particularly where no effective treatment alternative exists) must be weighed against the risks and consequences of ongoing toxicity. Optimally, this decision should be made jointly by the patient, the oncologist, and the neuro-ophthalmologist.</p><p>Tretinoin has not been associated with night blindness, but this side effect should be kept in mind given the occurrence in other members of its class, including fenretinide and <a class="drug drug_general" data-topicid="8582" href="/d/drug information/8582.html" rel="external">isotretinoin</a> [<a href="#rid283">283-288</a>].</p><p class="headingAnchor" id="H27978356"><span class="h3">Vincristine</span><span class="headingEndMark"> — </span>Vincristine-based regimens are uncommonly associated with cranial nerve palsies, leading to poor extraocular movement and diplopia, and poor eyelid closure with facial nerve involvement [<a href="#rid289">289-291</a>]. There have been reports of improvement over time [<a href="#rid291">291</a>]. Ocular involvement is likely a manifestation of known vincristine-associated neuropathy. (See  <a class="medical medical_review" href="/d/html/2836.html" rel="external">"Overview of neurologic complications of conventional non-platinum cancer chemotherapy", section on 'Vinca alkaloids'</a>.)</p><p>Rarely, a toxic optic neuropathy is seen causing reduced vision [<a href="#rid292">292,293</a>]. With discontinuation of therapy, vision improvement has been reported [<a href="#rid292">292</a>]. Histology showed loss of ganglion cells of the retina and atrophy of fibers of the optic nerve suggestive of direct toxicity [<a href="#rid293">293</a>].</p><p>We recommend discontinuation of therapy given the possibility of reversible cranial or optic nerve damage. However, the risks and benefits of stopping or continuing therapy should be made on an individual basis. Temporary monocular patching can relieve diplopia. If cranial nerve palsy is permanent, prism glasses or possibly surgical intervention can be tried. In the case of facial nerve palsy, frequent eye lubrication and possibly temporary tarsorrhaphy are recommended to prevent exposure keratopathy and complications. Referral to a specialist is recommended to follow these conditions.</p><p class="headingAnchor" id="H27978392"><span class="h1">SUMMARY AND RECOMMENDATIONS</span><span class="headingEndMark"> — </span>Although relatively uncommon, ocular side effects from systemically administered chemotherapy (particularly targeted agents) can be severe, disabling, and irreversible. While some can be managed symptomatically while chemotherapy is continued, others can be vision threatening and warrant immediate discontinuation of the drug.</p><p class="bulletIndent1"><span class="glyph">●</span>When a patient receiving chemotherapy presents with a specific ocular sign or symptom, it is important to delineate whether the complaint is due to the malignancy itself, a paraneoplastic phenomenon, or an effect of cancer treatment. Intraocular metastasis occurs most commonly in the uveal tract and can cause overlying serous retinal detachment. A dilated fundus examination, along with ocular imaging, can help differentiate a metastasis from a drug side effect. (See <a class="local">'Differentiating metastasis from drug toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Different compartments of the eye  (<a class="graphic graphic_figure graphicRef57690" href="/d/graphic/57690.html" rel="external">figure 1</a>) are preferentially affected by different agents. Presenting signs and symptoms can help localize which compartment of the eye (ie, the cornea, uvea [choroid, ciliary body, and iris], periocular and orbital tissue, retina, and/or optic nerve) is affected. (See <a class="local">'Localizing the compartment affected by ocular toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cornea and anterior segment toxicities are most common with the following agents (see <a class="local">'Cornea and anterior segment'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targeted/immunotherapy agents</strong> – Epidermal growth factor receptor (EGFR) inhibitors (<a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a>, <a class="drug drug_general" data-topicid="10336" href="/d/drug information/10336.html" rel="external">panitumumab</a>, and <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>), the human epidermal growth factor receptor 2 (HER2) inhibitor <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, the BRAF inhibitor <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, the immune checkpoint inhibitor <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">ipilimumab</a>, small-molecule tyrosine kinase inhibitors (TKIs) targeting BCR-ABL kinase and KIT (<a class="drug drug_general" data-topicid="9448" href="/d/drug information/9448.html" rel="external">nilotinib</a> and <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>), and <a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a>. (See <a class="local">'Molecularly targeted agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional chemotherapy</strong> – The alkylating agent <a class="drug drug_general" data-topicid="9173" href="/d/drug information/9173.html" rel="external">busulfan</a>, fluoropyrimidines, and anthracyclines and anthracenediones. (See <a class="local">'Traditional chemotherapy agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Uveitis is most common with the following agents (see <a class="local">'Uveitis and ocular inflammation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targeted/immunotherapy agents</strong> – <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a>, BRAF inhibitors (<a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, <a class="drug drug_general" data-topicid="89686" href="/d/drug information/89686.html" rel="external">dabrafenib</a>, and <a class="drug drug_general" data-topicid="118325" href="/d/drug information/118325.html" rel="external">encorafenib</a>), and the EGFR inhibitor <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>. (See <a class="local">'Molecularly targeted agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional chemotherapy</strong> – <a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">Cytarabine</a> and interferon. (See <a class="local">'Cytarabine and fludarabine'</a> above and <a class="local">'Interferon'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Periocular toxicities are most commonly seen with the following agents (see <a class="local">'Orbit and periorbital tissue'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targeted/immunotherapy agents</strong> – <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a>, EGFR inhibitors (<a class="drug drug_general" data-topicid="9209" href="/d/drug information/9209.html" rel="external">cetuximab</a> and <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>), the BRAF inhibitor <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, and <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. (See <a class="local">'Traditional chemotherapy agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional chemotherapy</strong> – <a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">Docetaxel</a>, antimetabolites (<a class="drug drug_general" data-topicid="8464" href="/d/drug information/8464.html" rel="external">fluorouracil</a> and <a class="drug drug_general" data-topicid="10098" href="/d/drug information/10098.html" rel="external">pemetrexed</a>), and the proteasome inhibitor <a class="drug drug_general" data-topicid="8509" href="/d/drug information/8509.html" rel="external">bortezomib</a>. (See <a class="local">'Traditional chemotherapy agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retinal toxicities are most commonly seen with the following agents (see <a class="local">'Retina'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targeted/immunotherapy agents</strong> – <a class="drug drug_general" data-topicid="16084" href="/d/drug information/16084.html" rel="external">Ipilimumab</a>, <a class="drug drug_general" data-topicid="10101" href="/d/drug information/10101.html" rel="external">trastuzumab</a>, <a class="drug drug_general" data-topicid="16798" href="/d/drug information/16798.html" rel="external">vemurafenib</a>, mitogen-activated protein kinase (MEK) inhibitors (<a class="drug drug_general" data-topicid="89685" href="/d/drug information/89685.html" rel="external">trametinib</a>, <a class="drug drug_general" data-topicid="105354" href="/d/drug information/105354.html" rel="external">cobimetinib</a>), <a class="drug drug_general" data-topicid="8736" href="/d/drug information/8736.html" rel="external">erlotinib</a>, steroid antagonists (<a class="drug drug_general" data-topicid="9972" href="/d/drug information/9972.html" rel="external">tamoxifen</a> and <a class="drug drug_general" data-topicid="10164" href="/d/drug information/10164.html" rel="external">toremifene</a>), and <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. (See <a class="local">'Molecularly targeted agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional chemotherapy</strong> – Platinum analogs (<a class="drug drug_general" data-topicid="9271" href="/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/d/drug information/9202.html" rel="external">carboplatin</a>, and <a class="drug drug_general" data-topicid="10180" href="/d/drug information/10180.html" rel="external">oxaliplatin</a>), antimetabolites (<a class="drug drug_general" data-topicid="9314" href="/d/drug information/9314.html" rel="external">cytarabine</a> and <a class="drug drug_general" data-topicid="8452" href="/d/drug information/8452.html" rel="external">fludarabine</a>), taxanes, <a class="drug drug_general" data-topicid="9659" href="/d/drug information/9659.html" rel="external">mitotane</a>, and the retinoic acid derivative all-trans-retinoic acid (tretinoin). (See <a class="local">'Traditional chemotherapy agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optic nerve toxicities are most common with the following agents (see <a class="local">'Optic nerve'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Targeted/immunotherapy agents</strong> – The anaplastic lymphoma kinase inhibitors (especially <a class="drug drug_general" data-topicid="16810" href="/d/drug information/16810.html" rel="external">crizotinib</a>) and <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a>. (See <a class="local">'Anaplastic lymphoma kinase inhibitors'</a> above and <a class="local">'Imatinib'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Traditional chemotherapy</strong> – Taxanes (<a class="drug drug_general" data-topicid="9381" href="/d/drug information/9381.html" rel="external">docetaxel</a> and <a class="drug drug_general" data-topicid="9735" href="/d/drug information/9735.html" rel="external">paclitaxel</a>), the vinca alkaloid <a class="drug drug_general" data-topicid="10045" href="/d/drug information/10045.html" rel="external">vincristine</a>, tretinoin, platinum analogs, <a class="drug drug_general" data-topicid="9206" href="/d/drug information/9206.html" rel="external">carmustine</a>, interferon, <a class="drug drug_general" data-topicid="9630" href="/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9660" href="/d/drug information/9660.html" rel="external">mitoxantrone</a>. (See <a class="local">'Traditional chemotherapy agents'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early referral to an ophthalmologist may help with management of eye symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the setting of ocular toxicity, the decision to stop or continue cancer therapy must be individualized. In many cases, the eye symptom can be managed symptomatically while the anticancer drug is continued. However, if vision is threatened, the benefits of continuing the specific chemotherapy drug (particularly where no effective treatment alternative exists) must be weighed against the risks and consequences of ongoing ocular toxicity. Optimally, this decision should be made jointly by the patient, the oncologist, and the ophthalmologist.</p><p></p><p class="headingAnchor" id="H62230183"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Jose S Pulido, MD, MS, MPH, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 28, 2018).</li><li><a class="nounderline abstract_t">Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:108.</a></li><li><a class="nounderline abstract_t">Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol 2009; 147:206.</a></li><li><a class="nounderline abstract_t">Lin P, Fintelmann RE, Khalifa YM, et al. Ocular surface disease secondary to vitamin A deficiency in the developed world: it still exists. Arch Ophthalmol 2011; 129:798.</a></li><li><a class="nounderline abstract_t">Samarawickrama C, Chew S, Watson S. Retinoic acid and the ocular surface. Surv Ophthalmol 2015; 60:183.</a></li><li><a class="nounderline abstract_t">Nichols KK, Foulks GN, Bron AJ, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011; 52:1922.</a></li><li><a class="nounderline abstract_t">Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996; 40:343.</a></li><li><a class="nounderline abstract_t">Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106:336.</a></li><li><a class="nounderline abstract_t">Foerster CG, Cursiefen C, Kruse FE. Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody). Cornea 2008; 27:612.</a></li><li><a class="nounderline abstract_t">Saint-Jean A, Sainz de la Maza M, Morral M, et al. Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases. Ophthalmology 2012; 119:1798.</a></li><li><a class="nounderline abstract_t">Ahn J, Wee WR, Lee JH, Hyon JY. Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer. Korean J Ophthalmol 2011; 25:355.</a></li><li><a class="nounderline abstract_t">Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140:509.</a></li><li><a class="nounderline abstract_t">Esmaeli B, Ahmadi MA, Rivera E, et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120:1180.</a></li><li><a class="nounderline abstract_t">Papavasileiou E, Prasad S, Freitag SK, et al. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature. Ocul Immunol Inflamm 2016; 24:140.</a></li><li><a class="nounderline abstract_t">Waikhom B, Fraunfelder FT, Henner WD. Severe ocular irritation and corneal deposits associated with capecitabine use. N Engl J Med 2000; 343:740.</a></li><li><a class="nounderline abstract_t">Modjtahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol 2013; 32:341.</a></li><li><a class="nounderline abstract_t">Cohen PR, Escudier SM, Kurzrock R. Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors. Am J Clin Dermatol 2011; 12:63.</a></li><li><a class="nounderline abstract_t">Bouché O, Brixi-Benmansour H, Bertin A, et al. Trichomegaly of the eyelashes following treatment with cetuximab. Ann Oncol 2005; 16:1711.</a></li><li><a class="nounderline abstract_t">Melichar B, Nemcová I. Eye complications of cetuximab therapy. Eur J Cancer Care (Engl) 2007; 16:439.</a></li><li><a class="nounderline abstract_t">Vaccaro M, Pollicino A, Barbuzza O, Guarneri B. Trichomegaly of the eyelashes following treatment with cetuximab. Clin Exp Dermatol 2009; 34:402.</a></li><li><a class="nounderline abstract_t">Rodriguez NA, Ascaso FJ. Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer. J Clin Oncol 2011; 29:e532.</a></li><li><a class="nounderline abstract_t">Specenier P, Koppen C, Vermorken JB. Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy. Ann Oncol 2007; 18:961.</a></li><li><a class="nounderline abstract_t">Dranko S, Kinney C, Ramanathan RK. Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer. Clin Colorectal Cancer 2006; 6:224.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125147s210lbl.pdf (Accessed on September 02, 2021).</li><li><a class="nounderline abstract_t">Tullo AB, Esmaeli B, Murray PI, et al. Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials. Eye (Lond) 2005; 19:729.</a></li><li><a class="nounderline abstract_t">Borkar DS, Lacouture ME, Basti S. Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review. Support Care Cancer 2013; 21:1167.</a></li><li><a class="nounderline abstract_t">Johnson KS, Levin F, Chu DS. Persistent corneal epithelial defect associated with erlotinib treatment. Cornea 2009; 28:706.</a></li><li><a class="nounderline abstract_t">Shin E, Lim DH, Han J, et al. Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors. BMC Ophthalmol 2020; 20:19.</a></li><li><a class="nounderline abstract_t">Chow VW, Jhanji V, Chi SC. Erlotinib-related corneal melting. Ophthalmology 2013; 120:1104.e1.</a></li><li class="breakAll">https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761210s000lbl.pdf (Accessed on June 02, 2021).</li><li><a class="nounderline abstract_t">Lim LT, Blum RA, Cheng CP, Hanifudin A. Bilateral anterior uveitis secondary to erlotinib. Eur J Clin Pharmacol 2010; 66:1277.</a></li><li><a class="nounderline abstract_t">Ali K, Kumar I, Usman-Saeed M, Usman Saeed M. Erlotinib-related bilateral anterior uveitis. BMJ Case Rep 2011; 2011.</a></li><li><a class="nounderline abstract_t">Roé E, García Muret MP, Marcuello E, et al. Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients. J Am Acad Dermatol 2006; 55:429.</a></li><li><a class="nounderline abstract_t">Celik T, Kosker M. Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature. Cont Lens Anterior Eye 2015; 38:59.</a></li><li><a class="nounderline abstract_t">Lane K, Goldstein SM. Erlotinib-associated trichomegaly. Ophthal Plast Reconstr Surg 2007; 23:65.</a></li><li><a class="nounderline abstract_t">Jazayeri F, Malhotra R. A case of acquired trichomegaly following treatment with erlotinib. BMJ Case Rep 2009; 2009.</a></li><li><a class="nounderline abstract_t">Garibaldi DC, Adler RA. Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab. Ophthal Plast Reconstr Surg 2007; 23:62.</a></li><li><a class="nounderline abstract_t">Carser JE, Summers YJ. Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer. J Thorac Oncol 2006; 1:1040.</a></li><li><a class="nounderline abstract_t">Desai RU, Rachakonda LP, Saffra NA. Trichomegaly secondary to erlotinib. Can J Ophthalmol 2009; 44:e65.</a></li><li><a class="nounderline abstract_t">Fabbrocini G, Panariello L, Cacciapuoti S, et al. Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases. Dermatitis 2012; 23:237.</a></li><li><a class="nounderline abstract_t">Munoz J, Hanbali AS. Epidermal growth factor receptor-induced hirsutism and trichomegaly. Mayo Clin Proc 2011; 86:e50.</a></li><li><a class="nounderline abstract_t">Papadopoulos R, Chasapi V, Bachariou A. Trichomegaly induced by erlotinib. Orbit 2008; 27:329.</a></li><li><a class="nounderline abstract_t">Saif MW, Gnanaraj J. Erlotinib-induced trichomegaly in a male patient with pancreatic cancer. Cutan Ocul Toxicol 2010; 29:62.</a></li><li><a class="nounderline abstract_t">Vergou T, Stratigos AJ, Karapanagiotou EM, et al. Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib. J Am Acad Dermatol 2010; 63:e56.</a></li><li><a class="nounderline abstract_t">Methvin AB, Gausas RE. Newly recognized ocular side effects of erlotinib. Ophthal Plast Reconstr Surg 2007; 23:63.</a></li><li><a class="nounderline abstract_t">Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13:1011.</a></li><li><a class="nounderline abstract_t">Saleh M, Bourcier T, Noel G, et al. Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol 2011; 50:477.</a></li><li><a class="nounderline abstract_t">Choe CH, McArthur GA, Caro I, et al. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib. Am J Ophthalmol 2014; 158:831.</a></li><li><a class="nounderline abstract_t">Guedj M, Quéant A, Funck-Brentano E, et al. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib. JAMA Ophthalmol 2014; 132:1421.</a></li><li><a class="nounderline abstract_t">Joshi L, Karydis A, Gemenetzi M, et al. Uveitis as a Result of MAP Kinase Pathway Inhibition. Case Rep Ophthalmol 2013; 4:279.</a></li><li><a class="nounderline abstract_t">Lim J, Lomax AJ, McNeil C, Harrisberg B. Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report. Ocul Immunol Inflamm 2016; :1.</a></li><li><a class="nounderline abstract_t">Draganova D, Kerger J, Caspers L, Willermain F. Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib. J Ophthalmic Inflamm Infect 2015; 5:17.</a></li><li><a class="nounderline abstract_t">Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2018; 19:603.</a></li><li><a class="nounderline abstract_t">Yin VT, Wiraszka TA, Tetzlaff M, et al. Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy. Ophthal Plast Reconstr Surg 2015; 31:e112.</a></li><li><a class="nounderline abstract_t">Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13:773.</a></li><li><a class="nounderline abstract_t">LoRusso PM, Krishnamurthi SS, Rinehart JJ, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin Cancer Res 2010; 16:1924.</a></li><li class="breakAll">United States Prescribing Information for trametinib available online at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0002ad27-779d-42ab-83b5-bc65453412a1 (Accessed on February 28, 2017).</li><li><a class="nounderline abstract_t">Niro A, Strippoli S, Alessio G, et al. Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series. Am J Ophthalmol 2015; 160:959.</a></li><li><a class="nounderline abstract_t">Haura EB, Ricart AD, Larson TG, et al. A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2010; 16:2450.</a></li><li><a class="nounderline abstract_t">Francis JH, Diamond EL, Chi P, et al. MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants. Ocul Oncol Pathol 2020; 6:159.</a></li><li><a class="nounderline abstract_t">Martinez-Garcia M, Banerji U, Albanell J, et al. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors. Clin Cancer Res 2012; 18:4806.</a></li><li><a class="nounderline abstract_t">Giuffrè C, Miserocchi E, Modorati G, et al. CENTRAL SEROUS CHORIORETINOPATHYLIKE MIMICKING MULTIFOCAL VITELLIFORM MACULAR DYSTROPHY: AN OCULAR SIDE EFFECT OF MITOGEN/EXTRACELLULAR SIGNAL-REGULATED KINASE INHIBITORS. Retin Cases Brief Rep 2016.</a></li><li><a class="nounderline abstract_t">Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 2010; 16:1613.</a></li><li><a class="nounderline abstract_t">Leijen S, Middleton MR, Tresca P, et al. Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors. Clin Cancer Res 2012; 18:4794.</a></li><li><a class="nounderline abstract_t">Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009; 69:6839.</a></li><li><a class="nounderline abstract_t">Urner-Bloch U, Urner M, Stieger P, et al. Transient MEK inhibitor-associated retinopathy in metastatic melanoma. Ann Oncol 2014; 25:1437.</a></li><li><a class="nounderline abstract_t">Schoenberger SD, Kim SJ. Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma. Case Rep Ophthalmol Med 2013; 2013:673796.</a></li><li><a class="nounderline abstract_t">Stjepanovic N, Velazquez-Martin JP, Bedard PL. Ocular toxicities of MEK inhibitors and other targeted therapies. Ann Oncol 2016; 27:998.</a></li><li><a class="nounderline abstract_t">De La Cruz-Merino, Di Guardo L, Grob J-J, et al. Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study. J Clin Oncol 2015; 33S: ASCO #9033.</a></li><li><a class="nounderline abstract_t">Barteselli G, Goodman GR, Patel Y, et al. Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Saf 2022; 45:1491.</a></li><li><a class="nounderline abstract_t">van der Noll R, Leijen S, Neuteboom GH, et al. Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities. Cancer Treat Rev 2013; 39:664.</a></li><li><a class="nounderline abstract_t">van Dijk EH, van Herpen CM, Marinkovic M, et al. Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma. Ophthalmology 2015; 122:1907.</a></li><li><a class="nounderline abstract_t">Dréno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 2017; 28:1137.</a></li><li><a class="nounderline abstract_t">Francis JH, Habib LA, Abramson DH, et al. Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy. Ophthalmology 2017; 124:1788.</a></li><li><a class="nounderline abstract_t">Prensky C, Marlow E, Gupta M, et al. Reversible Macular Lesions in the Setting of Oral Pan-Fibroblast Growth Factor Inhibitor for the Treatment of Bladder Cancer. J Vitreoretin Dis 2017; 2:111.</a></li><li><a class="nounderline abstract_t">Nishina T, Takahashi S, Iwasawa R, et al. Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs 2018; 36:424.</a></li><li><a class="nounderline abstract_t">Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol 2020; 21:671.</a></li><li class="breakAll">Javle MM, Roychowdhury S, Kelley RK, et al. Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement (abstract). J Clin Oncol 39,2021 (suppl3; abstr 265). https://meetinglibrary.asco.org/record/194241/abstract (Accessed on June 02, 2021).</li><li><a class="nounderline abstract_t">Gile JJ, Ou F-S, Mahipal A, et al. FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. JCO Precis Oncol 2021; 5:1228.</a></li><li class="breakAll">United States Prescribing Information for erdafitinib available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212018s000lbl.pdf (Accessed on April 18, 2019).</li><li><a class="nounderline abstract_t">Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 2018; 132:393.</a></li><li><a class="nounderline abstract_t">Bétrian S, Gomez-Roca C, Vigarios E, et al. Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors. JAMA Dermatol 2017; 153:723.</a></li><li><a class="nounderline abstract_t">Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol 2005; 12:1005.</a></li><li><a class="nounderline abstract_t">Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw 2014; 12:1077.</a></li><li><a class="nounderline abstract_t">Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother 2004; 27:478.</a></li><li><a class="nounderline abstract_t">Voskens C, Cavallaro A, Erdmann M, et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol 2012; 30:e356.</a></li><li><a class="nounderline abstract_t">Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005; 23:6043.</a></li><li><a class="nounderline abstract_t">Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep 2012; 6:423.</a></li><li><a class="nounderline abstract_t">Crosson JN, Laird PW, Debiec M, et al. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 2015; 38:80.</a></li><li><a class="nounderline abstract_t">Witmer MT. Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone. Ophthalmic Surg Lasers Imaging Retina 2017; 48:928.</a></li><li><a class="nounderline abstract_t">McElnea E, Ní Mhéalóid A, Moran S, et al. Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 2014; 33:424.</a></li><li><a class="nounderline abstract_t">McMillen B, Dhillon MS, Yong-Yow S. A rare case of thyroid storm. BMJ Case Rep 2016; 2016:10.1136/bcr.</a></li><li><a class="nounderline abstract_t">Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26:5950.</a></li><li><a class="nounderline abstract_t">Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521.</a></li><li><a class="nounderline abstract_t">Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA 2016; 315:1600.</a></li><li><a class="nounderline abstract_t">Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32:1020.</a></li><li class="breakAll">United States Prescribing Information for avelumab available online at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5cd725a1-2fa4-408a-a651-57a7b84b2118 (Accessed on April 17, 2017).</li><li class="breakAll">United States Prescribing Information for atezolizumab available online at: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6fa682c9-a312-4932-9831-f286908660ee (Accessed on April 17, 2017).</li><li><a class="nounderline abstract_t">Patnaik A, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. J Clin Oncol 2015; 33S: ASCO #8011.</a></li><li><a class="nounderline abstract_t">Acaba-Berrocal LA, Lucio-Alvarez JA, Mashayekhi A, et al. Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment. JAMA Ophthalmol 2018; 136:1205.</a></li><li><a class="nounderline abstract_t">Fujimura T, Kambayashi Y, Tanita K, et al. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol 2018; 45:735.</a></li><li><a class="nounderline abstract_t">Arai T, Harada K, Usui Y, et al. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol 2017; 44:975.</a></li><li class="breakAll">United States Prescribing Information for cemiplimab-rwlc available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf (Accessed on October 01, 2018).</li><li><a class="nounderline abstract_t">Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39:4073.</a></li><li class="breakAll">Crizotinib capsules. United States Prescribing Information. US National Library of Medicine. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202570s000lbl.pdf (Accessed on June 21, 2019).</li><li><a class="nounderline abstract_t">Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363:1693.</a></li><li><a class="nounderline abstract_t">Kazandjian D, Blumenthal GM, Chen HY, et al. FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements. Oncologist 2014; 19:e5.</a></li><li><a class="nounderline abstract_t">Malik SM, Maher VE, Bijwaard KE, et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014; 20:2029.</a></li><li><a class="nounderline abstract_t">Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013; 368:2385.</a></li><li><a class="nounderline abstract_t">Chun SG, Iyengar P, Gerber DE, et al. Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation. J Clin Oncol 2015; 33:e25.</a></li><li class="breakAll">United States Prescribing Information for crizotinib https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2a51b0de-47d6-455e-a94c-d2c737b04ff7#S5.5 (Accessed on March 07, 2017).</li><li><a class="nounderline abstract_t">Besse B, Salgia R, Bolomon B, et al. Visual Disturbances in Patients (PTS) with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib. Annals of Oncology 2012; 23S: ASCO #ix416.</a></li><li><a class="nounderline abstract_t">Muftuoglu O, Uçakhan OO, Kanpolat A. Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate. Eye Contact Lens 2006; 32:228.</a></li><li><a class="nounderline abstract_t">Tarafdar S, Lim LT, Collins CE, Ramaesh K. Tamoxifen keratopathy as seen with in-vivo confocal microscopy. Semin Ophthalmol 2012; 27:27.</a></li><li><a class="nounderline abstract_t">Pyrhönen S, Ellmén J, Vuorinen J, et al. Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer. Breast Cancer Res Treat 1999; 56:133.</a></li><li><a class="nounderline abstract_t">Bishop J, Murray R, Webster L, et al. Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer. Cancer Chemother Pharmacol 1992; 30:174.</a></li><li><a class="nounderline abstract_t">Kaiser-Kupfer MI, Lippman ME. Tamoxifen retinopathy. Cancer Treat Rep 1978; 62:315.</a></li><li><a class="nounderline abstract_t">Gianni L, Munzone E, Capri G, et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J Natl Cancer Inst 1995; 87:1169.</a></li><li><a class="nounderline abstract_t">Nayfield SG, Gorin MB. Tamoxifen-associated eye disease. A review. J Clin Oncol 1996; 14:1018.</a></li><li><a class="nounderline abstract_t">Bourla DH, Sarraf D, Schwartz SD. Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy. Am J Ophthalmol 2007; 144:126.</a></li><li><a class="nounderline abstract_t">Gorin MB, Day R, Costantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998; 125:493.</a></li><li><a class="nounderline abstract_t">McKeown CA, Swartz M, Blom J, Maggiano JM. Tamoxifen retinopathy. Br J Ophthalmol 1981; 65:177.</a></li><li><a class="nounderline abstract_t">Pavlidis NA, Petris C, Briassoulis E, et al. Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients. Cancer 1992; 69:2961.</a></li><li><a class="nounderline abstract_t">Yanyali AC, Freund KB, Sorenson JA, et al. Tamoxifen retinopathy in a male patient. Am J Ophthalmol 2001; 131:386.</a></li><li><a class="nounderline abstract_t">Tang R, Shields J, Schiffman J, et al. Retinal changes associated with tamoxifen treatment for breast cancer. Eye (Lond) 1997; 11 ( Pt 3):295.</a></li><li><a class="nounderline abstract_t">Dogan SS, Esmaeli B. Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor. Hematol Oncol Clin North Am 2009; 23:109.</a></li><li><a class="nounderline abstract_t">Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472.</a></li><li><a class="nounderline abstract_t">Fraunfelder FW, Solomon J, Druker BJ, et al. Ocular side-effects associated with imatinib mesylate (Gleevec). J Ocul Pharmacol Ther 2003; 19:371.</a></li><li><a class="nounderline abstract_t">Esmaeli B, Prieto VG, Butler CE, et al. Severe periorbital edema secondary to STI571 (Gleevec). Cancer 2002; 95:881.</a></li><li><a class="nounderline abstract_t">Esmaeli B, Diba R, Ahmadi MA, et al. Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec). Eye (Lond) 2004; 18:760.</a></li><li><a class="nounderline abstract_t">Radaelli F, Vener C, Ripamonti F, et al. Conjunctival hemorrhagic events associated with imatinib mesylate. Int J Hematol 2007; 86:390.</a></li><li><a class="nounderline abstract_t">Breccia M, Gentilini F, Cannella L, et al. Ocular side effects in chronic myeloid leukemia patients treated with imatinib. Leuk Res 2008; 32:1022.</a></li><li><a class="nounderline abstract_t">Christoforidis JB, DeAngelo DJ, D'Amico DJ. Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia. Am J Ophthalmol 2003; 135:398.</a></li><li><a class="nounderline abstract_t">Gulati AP, Saif MW. Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST). Anticancer Res 2012; 32:1375.</a></li><li><a class="nounderline abstract_t">DeLuca C, Shenouda-Awad N, Haskes C, Wrzesinski S. Imatinib mesylate (Gleevec) induced unilateral optic disc edema. Optom Vis Sci 2012; 89:e16.</a></li><li><a class="nounderline abstract_t">Georgalas I, Pavesio C, Ezra E. Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect. Graefes Arch Clin Exp Ophthalmol 2007; 245:1585.</a></li><li><a class="nounderline abstract_t">Kusumi E, Arakawa A, Kami M, et al. Visual disturbance due to retinal edema as a complication of imatinib. Leukemia 2004; 18:1138.</a></li><li><a class="nounderline abstract_t">Kwon SI, Lee DH, Kim YJ. Optic disc edema as a possible complication of Imatinib mesylate (Gleevec). Jpn J Ophthalmol 2008; 52:331.</a></li><li><a class="nounderline abstract_t">Masood I, Negi A, Dua HS. Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery. J Cataract Refract Surg 2005; 31:2427.</a></li><li><a class="nounderline abstract_t">Govind Babu K, Attili VS, Bapsy PP, Anupama G. Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia. Int Ophthalmol 2007; 27:43.</a></li><li><a class="nounderline abstract_t">Yeh S, Fine HA, Smith JA. Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. Cornea 2009; 28:699.</a></li><li><a class="nounderline abstract_t">Cho JH, Kim KM, Kwon M, et al. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest New Drugs 2012; 30:2008.</a></li><li><a class="nounderline abstract_t">Maurizot A, Beressi JP, Manéglier B, et al. Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion. Blood Cancer J 2014; 4:e247.</a></li><li><a class="nounderline abstract_t">Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial. Lancet 2019; 394:478.</a></li><li><a class="nounderline abstract_t">Bohn M, Bravo-Ljubetic L, Lee RWJ, Petrushkin H. Ibrutinib-related uveitis: A report of two severe cases. Eur J Ophthalmol 2022; 32:NP94.</a></li><li><a class="nounderline abstract_t">Mehraban Far P, Rullo J, Farmer J, Urton T. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia. Ocul Immunol Inflamm 2022; 30:1005.</a></li><li class="breakAll">US prescribing information for belantamab mafodotin available online at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=16a160a4-3ec0-4ddf-99ce-05912dd3382d (Accessed on August 18, 2020).</li><li><a class="nounderline abstract_t">Mohan M, Rein LE, Thalambedu N, et al. Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience. Am J Hematol 2022; 97:E451.</a></li><li><a class="nounderline abstract_t">Rosenberg JE, O'Donnell PH, Balar AV, et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. J Clin Oncol 2019; 37:2592.</a></li><li class="breakAll">United States Prescribing Information for enfortumaab vedotin available online at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761137s000lbl.pdf (Accessed on December 19, 2019).</li><li class="breakAll">TIVDAK TM (tisotumab vedotin-tftv) for injection, for intravenous use. U.S. Food and Drug Administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761208Orig1s000lbledt.pdf (Accessed on January 03, 2023).</li><li><a class="nounderline abstract_t">Grob SR, Jakobiec FA, Rashid A, Yoon MK. Chalazia associated with bortezomib therapy for multiple myeloma. Ophthalmology 2014; 121:1845.</a></li><li><a class="nounderline abstract_t">Fraunfelder FW, Yang HK. Association Between Bortezomib Therapy and Eyelid Chalazia. JAMA Ophthalmol 2016; 134:88.</a></li><li><a class="nounderline abstract_t">Yun C, Mukhi N, Kremer V, et al. Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy. Hematol Rep 2015; 7:5729.</a></li><li><a class="nounderline abstract_t">Veys MC, Delforge M, Mombaerts I. Treatment With Doxycycline for Severe Bortezomib-Associated Blepharitis. Clin Lymphoma Myeloma Leuk 2016; 16:e109.</a></li><li><a class="nounderline abstract_t">Burstein HJ, Manola J, Younger J, et al. Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol 2000; 18:1212.</a></li><li><a class="nounderline abstract_t">Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol 2013; 31:2123.</a></li><li><a class="nounderline abstract_t">Tabernero J, Climent MA, Lluch A, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 2004; 15:1358.</a></li><li><a class="nounderline abstract_t">Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502.</a></li><li><a class="nounderline abstract_t">Esmaeli B, Hortobagyi GN, Esteva FJ, et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002; 109:1188.</a></li><li><a class="nounderline abstract_t">Esmaeli B, Valero V. Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important? J Clin Oncol 2013; 31:2076.</a></li><li><a class="nounderline abstract_t">Esmaeli B, Hidaji L, Adinin RB, et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003; 98:504.</a></li><li><a class="nounderline abstract_t">Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 2001; 119:1802.</a></li><li><a class="nounderline abstract_t">Scaioli V, Caraceni A, Martini C, et al. Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. J Neurooncol 2006; 77:79.</a></li><li><a class="nounderline abstract_t">Seidman AD, Barrett S, Canezo S. Photopsia during 3-hour paclitaxel administration at doses &gt; or = 250 mg/m2. J Clin Oncol 1994; 12:1741.</a></li><li><a class="nounderline abstract_t">Capri G, Munzone E, Tarenzi E, et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994; 86:1099.</a></li><li><a class="nounderline abstract_t">Hofstra LS, de Vries EG, Willemse PH. Ophthalmic toxicity following paclitaxel infusion. Ann Oncol 1997; 8:1053.</a></li><li><a class="nounderline abstract_t">Moloney TP, Xu W, Rallah-Baker K, et al. Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. BMC Ophthalmol 2014; 14:18.</a></li><li><a class="nounderline abstract_t">Georgakopoulos CD, Makri OE, Vasilakis P, Exarchou A. Angiographically silent cystoid macular oedema secondary to paclitaxel therapy. Clin Exp Optom 2012; 95:233.</a></li><li><a class="nounderline abstract_t">Joshi MM, Garretson BR. Paclitaxel maculopathy. Arch Ophthalmol 2007; 125:709.</a></li><li><a class="nounderline abstract_t">Murphy CG, Walsh JB, Hudis CA, et al. Cystoid macular edema secondary to nab-paclitaxel therapy. J Clin Oncol 2010; 28:e684.</a></li><li><a class="nounderline abstract_t">Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optom Vis Sci 2003; 80:277.</a></li><li><a class="nounderline abstract_t">Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007; 22:151.</a></li><li><a class="nounderline abstract_t">Smith SV, Benz MS, Brown DM. Cystoid macular edema secondary to albumin-bound paclitaxel therapy. Arch Ophthalmol 2008; 126:1605.</a></li><li><a class="nounderline abstract_t">Eiseman AS, Flanagan JC, Brooks AB, et al. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthal Plast Reconstr Surg 2003; 19:216.</a></li><li><a class="nounderline abstract_t">Hamersley J, Luce JK, Florentz TR, et al. Excessive lacrimation from fluorouracil treatment. JAMA 1973; 225:747.</a></li><li><a class="nounderline abstract_t">Hassan A, Hurwitz JJ, Burkes RL. Epiphora in patients receiving systemic 5-fluorouracil therapy. Can J Ophthalmol 1998; 33:14.</a></li><li><a class="nounderline abstract_t">Karamitsos A, Kokkas V, Goulas A, et al. Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen. Hippokratia 2013; 17:120.</a></li><li><a class="nounderline abstract_t">Caravella LP Jr, Burns JA, Zangmeister M. Punctal-canalicular stenosis related to systemic fluorouracil therapy. Arch Ophthalmol 1981; 99:284.</a></li><li><a class="nounderline abstract_t">Insler MS, Helm CJ. Ankyloblepharon associated with systemic 5-fluorouracil treatment. Ann Ophthalmol 1987; 19:374.</a></li><li><a class="nounderline abstract_t">Prasad S, Kamath GG, Phillips RP. Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy. Acta Ophthalmol Scand 2000; 78:110.</a></li><li><a class="nounderline abstract_t">Seiff SR, Shorr N, Adams T. Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapy. Cancer 1985; 56:2148.</a></li><li><a class="nounderline abstract_t">Straus DJ, Mausolf FA, Ellerby RA, McCracken JD. Cicatricial ectropion secondary to 5-fluorouracil therapy. Med Pediatr Oncol 1977; 3:15.</a></li><li><a class="nounderline abstract_t">Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. Doc Ophthalmol 1995; 90:1.</a></li><li><a class="nounderline abstract_t">Haidak DJ, Hurwitz BS, Yeung KY. Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann Intern Med 1978; 88:657.</a></li><li><a class="nounderline abstract_t">Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294:405.</a></li><li><a class="nounderline abstract_t">Shi-Xia X, Xian-Hua T, Hai-Qin X, et al. Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis. Leuk Lymphoma 2010; 51:50.</a></li><li><a class="nounderline abstract_t">Horwitz M, Auquier P, Barlogis V, et al. Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study. Br J Haematol 2015; 168:518.</a></li><li><a class="nounderline abstract_t">Holmström G, Borgström B, Calissendorff B. Cataract in children after bone marrow transplantation: relation to conditioning regimen. Acta Ophthalmol Scand 2002; 80:211.</a></li><li><a class="nounderline abstract_t">Guthoff T, Tietze B, Meinhardt B, et al. Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics. Ophthalmologica 2010; 224:308.</a></li><li><a class="nounderline abstract_t">Mori T, Watanabe M, Kurotori-Sotome T, et al. Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 42:197.</a></li><li><a class="nounderline abstract_t">Herzig RH, Wolff SN, Lazarus HM, et al. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62:361.</a></li><li><a class="nounderline abstract_t">Krema H, Santiago RA, Schuh A, Pavlin CJ. Cytarabine toxicity of the corneal endothelium. Ann Hematol 2013; 92:559.</a></li><li><a class="nounderline abstract_t">Dhillon VK, Faraj LA, Elalfy MS, et al. Corneal microcysts. Br J Ophthalmol 2014; 98:138, 147.</a></li><li><a class="nounderline abstract_t">Lazarus HM, Hartnett ME, Reed MD, et al. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol 1987; 104:476.</a></li><li><a class="nounderline abstract_t">Moberg J, Carlsson M, Holm C, Koranyi G. Severe anterior uveitis as a complication of high-dose cytosine-arabinoside. Acta Ophthalmol 2009; 87:922.</a></li><li><a class="nounderline abstract_t">Planer D, Cukierman T, Liebster D, et al. Anterior uveitis as a complication of treatment with high dose cytosine-arabinoside. Am J Hematol 2004; 76:304.</a></li><li><a class="nounderline abstract_t">Vogler WR, Winton EF, Heffner LT, et al. Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation. Bone Marrow Transplant 1990; 6:405.</a></li><li><a class="nounderline abstract_t">Wiznia RA, Rose A, Levy AL. Occlusive microvascular retinopathy with optic disc and retinal neovascularization in acute lymphocytic leukemia. Retina 1994; 14:253.</a></li><li><a class="nounderline abstract_t">Bishop RJ, Ding X, Heller CK 3rd, et al. Rapid vision loss associated with fludarabine administration. Retina 2010; 30:1272.</a></li><li><a class="nounderline abstract_t">Spiers AS, Ruckdeschel JC, Horton J. Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms. Scand J Haematol 1984; 32:130.</a></li><li><a class="nounderline abstract_t">Grever MR, Bisaccia E, Scarborough DA, et al. An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma. Blood 1983; 61:279.</a></li><li><a class="nounderline abstract_t">Cassileth PA, Cheuvart B, Spiers AS, et al. Pentostatin induces durable remissions in hairy cell leukemia. J Clin Oncol 1991; 9:243.</a></li><li><a class="nounderline abstract_t">Kraut EH, Bouroncle BA, Grever MR. Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 1989; 7:168.</a></li><li><a class="nounderline abstract_t">Grever MR, Leiby JM, Kraut EH, et al. Low-dose deoxycoformycin in lymphoid malignancy. J Clin Oncol 1985; 3:1196.</a></li><li><a class="nounderline abstract_t">Winick N, Buchanan GR, Murphy SB, et al. Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study. Med Pediatr Oncol 1988; 16:327.</a></li><li><a class="nounderline abstract_t">Margolis J, Grever MR. Pentostatin (Nipent): a review of potential toxicity and its management. Semin Oncol 2000; 27:9.</a></li><li><a class="nounderline abstract_t">Doroshow JH, Locker GY, Gaasterland DE, et al. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. Cancer 1981; 48:2158.</a></li><li><a class="nounderline abstract_t">Balachandran C, McCluskey PJ, Champion GD, Halmagyi GM. Methotrexate-induced optic neuropathy. Clin Exp Ophthalmol 2002; 30:440.</a></li><li><a class="nounderline abstract_t">Clare G, Colley S, Kennett R, Elston JS. Reversible optic neuropathy associated with low-dose methotrexate therapy. J Neuroophthalmol 2005; 25:109.</a></li><li><a class="nounderline abstract_t">Johansson BA. Visual field defects during low-dose methotrexate therapy. Doc Ophthalmol 1992; 79:91.</a></li><li><a class="nounderline abstract_t">Sbeity ZH, Baydoun L, Schmidt S, Loeffler KU. Visual field changes in methotrexate therapy. Case report and review of the literature. J Med Liban 2006; 54:164.</a></li><li><a class="nounderline abstract_t">Whittle SL, Hughes RA. Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. Rheumatology (Oxford) 2004; 43:267.</a></li><li><a class="nounderline abstract_t">Schallier D, Decoster L, Fontaine C, De Grève J. Pemetrexed-induced eyelid edema: incidence and clinical manifestations. Anticancer Res 2010; 30:5185.</a></li><li><a class="nounderline abstract_t">Kurata T, Tamura K, Okamoto I, et al. Pemetrexed-induced edema of the eyelid. Lung Cancer 2006; 54:241.</a></li><li><a class="nounderline abstract_t">Eguia B, Ruppert AM, Fillon J, et al. Skin toxicities compromise prolonged pemetrexed treatment. J Thorac Oncol 2011; 6:2083.</a></li><li><a class="nounderline abstract_t">Guhl G, Diaz-Ley B, Sanchez-Perez J, et al. Pemetrexed-induced edema of the eyelid. Lung Cancer 2010; 69:249.</a></li><li><a class="nounderline abstract_t">Curran CF, Luce JK. Ocular adverse reactions associated with adriamycin (doxorubicin). Am J Ophthalmol 1989; 108:709.</a></li><li><a class="nounderline abstract_t">Wickremasinghe S, Dansingani KK, Tranos P, et al. Ocular presentations of breast cancer. Acta Ophthalmol Scand 2007; 85:133.</a></li><li><a class="nounderline abstract_t">Cardoso F, Ferreira Filho AF, Crown J, et al. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study. Anticancer Res 2001; 21:789.</a></li><li><a class="nounderline abstract_t">Wang WS, Tzeng CH, Chiou TJ, et al. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma. Jpn J Clin Oncol 1997; 27:154.</a></li><li><a class="nounderline abstract_t">Ammatuna E, Montesinos P, Hasan SK, et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011; 96:621.</a></li><li><a class="nounderline abstract_t">Le Deley MC, Suzan F, Cutuli B, et al. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol 2007; 25:292.</a></li><li><a class="nounderline abstract_t">Ko MW, Tamhankar MA, Volpe NJ, et al. Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis. J Neurol Sci 2008; 273:144.</a></li><li><a class="nounderline abstract_t">Al-Muammar AM, Al-Mudhaiyan TM, Al Otaibi M, et al. Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection. Int Ophthalmol 2010; 30:611.</a></li><li><a class="nounderline abstract_t">Lim JH, Lee YN, Kim YS, et al. Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C. Korean J Hepatol 2011; 17:61.</a></li><li><a class="nounderline abstract_t">Sylvestre DL, Disston AR, Bui DP. Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy. J Viral Hepat 2003; 10:467.</a></li><li><a class="nounderline abstract_t">Touitou V, Bodaghi B, Cassoux N, et al. Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C. Am J Ophthalmol 2005; 140:949.</a></li><li><a class="nounderline abstract_t">Foon KA, Roth MS, Bunn PA Jr. Interferon therapy of non-Hodgkin's lymphoma. Cancer 1987; 59:601.</a></li><li><a class="nounderline abstract_t">Hernández-Núñez A, Fernández-Herrera J, Buceta LR, García-Díez A. Trichomegaly following treatment with interferon alpha-2b. Lancet 2002; 359:1107.</a></li><li><a class="nounderline abstract_t">Howaizi M. Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C. J Gastroenterol Hepatol 2005; 20:1945.</a></li><li><a class="nounderline abstract_t">Ozdoğan M, Gür G, Kadayifcilar S, et al. An unusual adverse effect of interferon: hypertrichosis of the eyelashes. J Interferon Cytokine Res 2000; 20:633.</a></li><li><a class="nounderline abstract_t">Sacchi S, Kantarjian H, O'Brien S, et al. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Clin Oncol 1995; 13:2401.</a></li><li><a class="nounderline abstract_t">Berglund EF, Burton GV, Mills GM, Nichols GM. Hypertrichosis of the eyelashes associated with interferon-alpha therapy for chronic granulocytic leukemia. South Med J 1990; 83:363.</a></li><li><a class="nounderline abstract_t">Kadayifcilar S, Boyacioglu S, Kart H, et al. Ocular complications with high-dose interferon alpha in chronic active hepatitis. Eye (Lond) 1999; 13 ( Pt 2):241.</a></li><li><a class="nounderline abstract_t">Esmaeli B, Koller C, Papadopoulos N, Romaguera J. Interferon-induced retinopathy in asymptomatic cancer patients. Ophthalmology 2001; 108:858.</a></li><li><a class="nounderline abstract_t">Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993; 111:350.</a></li><li><a class="nounderline abstract_t">Hejny C, Sternberg P, Lawson DH, et al. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001; 131:782.</a></li><li><a class="nounderline abstract_t">Tu KL, Bowyer J, Schofield K, Harding S. Severe interferon associated retinopathy. Br J Ophthalmol 2003; 87:247.</a></li><li><a class="nounderline abstract_t">Cuthbertson FM, Davies M, McKibbin M. Is screening for interferon retinopathy in hepatitis C justified? Br J Ophthalmol 2004; 88:1518.</a></li><li><a class="nounderline abstract_t">Hayasaka S, Nagaki Y, Matsumoto M, Sato S. Interferon associated retinopathy. Br J Ophthalmol 1998; 82:323.</a></li><li><a class="nounderline abstract_t">Jain K, Lam WC, Waheeb S, et al. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85:1171.</a></li><li><a class="nounderline abstract_t">Lim JW, Shin MC. Pegylated-interferon-associated retinopathy in chronic hepatitis patients. Ophthalmologica 2010; 224:224.</a></li><li><a class="nounderline abstract_t">Malik NN, Sheth HG, Ackerman N, et al. A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK. Br J Ophthalmol 2008; 92:256.</a></li><li><a class="nounderline abstract_t">Zegans ME, Anninger W, Chapman C, Gordon SR. Ocular manifestations of hepatitis C virus infection. Curr Opin Ophthalmol 2002; 13:423.</a></li><li><a class="nounderline abstract_t">Kim ET, Kim LH, Lee JI, Chin HS. Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin. Jpn J Ophthalmol 2009; 53:598.</a></li><li><a class="nounderline abstract_t">Nicolò M, Artioli S, La Mattina GC, et al. Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin. Eur J Ophthalmol 2005; 15:811.</a></li><li><a class="nounderline abstract_t">Kiratli H, Irkeç M. Presumed interferon-associated bilateral macular arterial branch obstruction. Eye (Lond) 2000; 14:920.</a></li><li><a class="nounderline abstract_t">Nagaoka T, Sato E, Takahashi A, et al. Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C. Invest Ophthalmol Vis Sci 2007; 48:368.</a></li><li><a class="nounderline abstract_t">Chisholm JA, Williams G, Spence E, et al. Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation. Aliment Pharmacol Ther 2005; 21:723.</a></li><li><a class="nounderline abstract_t">Mousa N, Besheer T, Gad Y, et al. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes? J Ocul Pharmacol Ther 2013; 29:345.</a></li><li><a class="nounderline abstract_t">Manesis EK, Petrou C, Brouzas D, Hadziyannis S. Optic tract neuropathy complicating low-dose interferon treatment. J Hepatol 1994; 21:474.</a></li><li><a class="nounderline abstract_t">Norcia F, Di Maria A, Prandini F, Redaelli C. Natural interferon therapy: optic nerve ischemic damage? Ophthalmologica 1999; 213:339.</a></li><li><a class="nounderline abstract_t">Purvin VA. Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 1995; 113:1041.</a></li><li><a class="nounderline abstract_t">Kiuchi K, Kitagawa C, Miyashiro M. [Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon]. Nippon Ganka Gakkai Zasshi 2009; 113:16.</a></li><li><a class="nounderline abstract_t">Lohmann CP, Kroher G, Bogenrieder T, et al. Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma. Lancet 1999; 353:1326.</a></li><li><a class="nounderline abstract_t">Shahidullah AB, Cerulli MA, Berman DH. Interferon may cause retinopathy during hepatitis therapy. Am J Gastroenterol 1995; 90:1543.</a></li><li><a class="nounderline abstract_t">Sene D, Touitou V, Bodaghi B, et al. Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C. World J Gastroenterol 2007; 13:3137.</a></li><li><a class="nounderline abstract_t">Wei YH, Wang IH, Woung LC, Jou JR. Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C. Ocul Immunol Inflamm 2009; 17:191.</a></li><li><a class="nounderline abstract_t">Chan JW. Bilateral non-arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C. Eye (Lond) 2007; 21:877.</a></li><li><a class="nounderline abstract_t">Manesis EK, Moschos M, Brouzas D, et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27:1421.</a></li><li><a class="nounderline abstract_t">Berg KT, Nelson B, Harrison AR, et al. Pegylated interferon alpha-associated optic neuropathy. J Neuroophthalmol 2010; 30:117.</a></li><li><a class="nounderline abstract_t">Dulz S, Asselborn NH, Dieckmann KP, et al. Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer. J Cancer Res Clin Oncol 2017; 143:1319.</a></li><li><a class="nounderline abstract_t">Li Y, Li Y, Li J, et al. Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review. Onco Targets Ther 2014; 7:1361.</a></li><li><a class="nounderline abstract_t">Das A, Ranjan R, Shah PK, Narendran V. Paclitaxel- and/or cyclophosphamide-induced severe ischaemic retinopathy. Clin Exp Ophthalmol 2020; 48:1113.</a></li><li><a class="nounderline abstract_t">Elhusseiny AM, Smiddy WE. Carboplatin- and/or paclitaxel-induced ischemic retinopathy. Can J Ophthalmol 2020; 55:e95.</a></li><li><a class="nounderline abstract_t">Wang MY, Arnold AC, Vinters HV, Glasgow BJ. Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy. Am J Ophthalmol 2000; 130:367.</a></li><li><a class="nounderline abstract_t">Feun LG, Wallace S, Stewart DJ, et al. Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors. Cancer 1984; 54:794.</a></li><li><a class="nounderline abstract_t">Hilliard LM, Berkow RL, Watterson J, et al. Retinal toxicity associated with cisplatin and etoposide in pediatric patients. Med Pediatr Oncol 1997; 28:310.</a></li><li><a class="nounderline abstract_t">Kupersmith MJ, Seiple WH, Holopigian K, et al. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am J Ophthalmol 1992; 113:435.</a></li><li><a class="nounderline abstract_t">Marmor MF. Negative-type electroretinogram from cisplatin toxicity. Doc Ophthalmol 1993; 84:237.</a></li><li><a class="nounderline abstract_t">Miller DF, Bay JW, Lederman RJ, et al. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas. Ophthalmology 1985; 92:402.</a></li><li><a class="nounderline abstract_t">Lewis P, Waqar S, Yiannakis D, Raman V. Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma. Case Rep Oncol 2014; 7:29.</a></li><li><a class="nounderline abstract_t">Rankin EM, Pitts JF. Ophthalmic toxicity during carboplatin therapy. Ann Oncol 1993; 4:337.</a></li><li><a class="nounderline abstract_t">Painhas T, Amorim M, Soares R, et al. Idiopathic intracranial hypertension and oxaliplatin: a causal association? Cutan Ocul Toxicol 2015; 34:237.</a></li><li><a class="nounderline abstract_t">Shingleton BJ, Bienfang DC, Albert DM, et al. Ocular toxicity associated with high-dose carmustine. Arch Ophthalmol 1982; 100:1766.</a></li><li><a class="nounderline abstract_t">Khawly JA, Rubin P, Petros W, et al. Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer. Ophthalmology 1996; 103:87.</a></li><li><a class="nounderline abstract_t">Johnson DW, Cagnoni PJ, Schossau TM, et al. Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support. Bone Marrow Transplant 1999; 24:785.</a></li><li><a class="nounderline abstract_t">Hoffman DL, Mattox VR. Treatment of adrenocortical carcinoma with o,p'-DDD. Med Clin North Am 1972; 56:999.</a></li><li><a class="nounderline abstract_t">Hutter AM Jr, Kayhoe DE. Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients. Am J Med 1966; 41:581.</a></li><li><a class="nounderline abstract_t">Abu el-Asrar AM, al-Momen AK, Harakati MS. Terson's syndrome in a patient with acute promyelocytic leukemia on all-trans retinoic acid treatment. Doc Ophthalmol 1993; 84:373.</a></li><li><a class="nounderline abstract_t">Guirgis MF, Lueder GT. Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management. J AAPOS 2003; 7:432.</a></li><li><a class="nounderline abstract_t">Costa A, Malone W, Perloff M, et al. Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol 1989; 25:805.</a></li><li><a class="nounderline abstract_t">Marmor MF, Jain A, Moshfeghi D. Total rod ERG suppression with high dose compassionate Fenretinide usage. Doc Ophthalmol 2008; 117:257.</a></li><li><a class="nounderline abstract_t">Modiano MR, Dalton WS, Lippman SM, et al. Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma. Invest New Drugs 1990; 8:317.</a></li><li><a class="nounderline abstract_t">Brown RD, Grattan CE. Visual toxicity of synthetic retinoids. Br J Ophthalmol 1989; 73:286.</a></li><li><a class="nounderline abstract_t">Denman S, Weleber R, Hanifin JM, et al. Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne. J Am Acad Dermatol 1986; 14:692.</a></li><li><a class="nounderline abstract_t">Weleber RG, Denman ST, Hanifin JM, Cunningham WJ. Abnormal retinal function associated with isotretinoin therapy for acne. Arch Ophthalmol 1986; 104:831.</a></li><li><a class="nounderline abstract_t">Albert DM, Wong VG, Henderson ES. Ocular complications of vincristine therapy. Arch Ophthalmol 1967; 78:709.</a></li><li><a class="nounderline abstract_t">Sarkar S, Deb AR, Saha K, Das CS. Simultaneous isolated bilateral facial palsy: a rare vincristine-associated toxicity. Indian J Med Sci 2009; 63:355.</a></li><li><a class="nounderline abstract_t">Toker E, Yenice O, Oğüt MS. Isolated abducens nerve palsy induced by vincristine therapy. J AAPOS 2004; 8:69.</a></li><li><a class="nounderline abstract_t">Norton SW, Stockman JA 3rd. Unilateral optic neuropathy following vincristine chemotherapy. J Pediatr Ophthalmol Strabismus 1979; 16:190.</a></li><li><a class="nounderline abstract_t">Sanderson PA, Kuwabara T, Cogan DG. Optic neuropathy presumably caused by vincristine therapy. Am J Ophthalmol 1976; 81:146.</a></li></ol></div><div id="topicVersionRevision">Topic 96203 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0, November 2017, National Institutes of Health, National Cancer Institute. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf (Accessed on March 28, 2018).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17508118" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Methodologies to diagnose and monitor dry eye disease: report of the Diagnostic Methodology Subcommittee of the International Dry Eye WorkShop (2007).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18848318" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21670349" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Ocular surface disease secondary to vitamin A deficiency in the developed world: it still exists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25890622" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Retinoic acid and the ocular surface.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21450913" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The international workshop on meibomian gland dysfunction: executive summary.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8779082" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Meibomian gland dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19277245" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520515" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Persisting corneal erosion under cetuximab (Erbitux) treatment (epidermal growth factor receptor antibody).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22584020" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Ocular adverse events of systemic inhibitors of the epidermal growth factor receptor: report of 5 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21976946" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16196117" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12215091" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Docetaxel secretion in tears: association with lacrimal drainage obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25760920" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979776" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Severe ocular irritation and corneal deposits associated with capecitabine use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23713627" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20726623" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cetuximab-associated elongation of the eyelashes: case report and review of eyelash trichomegaly secondary to epidermal growth factor receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972283" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Trichomegaly of the eyelashes following treatment with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17760931" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Eye complications of cetuximab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19120397" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Trichomegaly of the eyelashes following treatment with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21483009" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17442661" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Diffuse punctate keratitis in a patient treated with cetuximab as monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026793" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17026793" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Ocular toxicity related to cetuximab monotherapy in patients with colorectal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15688060" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23151647" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19512896" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Persistent corneal epithelial defect associated with erlotinib treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31918686" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23642754" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Erlotinib-related corneal melting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23642754" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Erlotinib-related corneal melting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20680254" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Bilateral anterior uveitis secondary to erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22694887" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Erlotinib-related bilateral anterior uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908348" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25249292" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ocular side effects and trichomegaly of eyelashes induced by erlotinib: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17237698" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Erlotinib-associated trichomegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21687012" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : A case of acquired trichomegaly following treatment with erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17237696" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cicatricial ectropion associated with treatment of metastatic colorectal cancer with cetuximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409992" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Trichomegaly of the eyelashes after treatment with erlotinib in non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20052001" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Trichomegaly secondary to erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23010833" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Trichomegaly of the eyelashes during therapy with epidermal growth factor receptor inhibitors: report of 3 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22033260" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epidermal growth factor receptor-induced hirsutism and trichomegaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18716976" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Trichomegaly induced by erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19954400" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Erlotinib-induced trichomegaly in a male patient with pancreatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20633793" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Facial hypertrichosis and trichomegaly developing in patients treated with the epidermal growth factor receptor inhibitor erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17237697" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Newly recognized ocular side effects of erlotinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22954507" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21303229" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Bilateral macular ischemia and severe visual loss following trastuzumab therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25036880" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25125216" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Uveitis in Patients With Late-Stage Cutaneous Melanoma Treated With Vemurafenib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24474928" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Uveitis as a Result of MAP Kinase Pathway Inhibition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27892777" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Uveitis and Papillitis in the Setting of Dabrafenib and Trametinib Therapy for Metastatic Melanoma: A Case Report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26078801" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29573941" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24833447" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Cutaneous Eyelid Neoplasms as a Toxicity of Vemurafenib Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22805291" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20215549" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20215549" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26231307" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Ocular Toxicity in Metastatic Melanoma Patients Treated With Mitogen-Activated Protein Kinase Kinase Inhibitors: A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332327" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32509759" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : MEK Inhibitor-Associated Central Retinal Vein Occlusion Associated with Hyperhomocysteinemia and MTHFR Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22761467" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27902541" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : CENTRAL SEROUS CHORIORETINOPATHYLIKE MIMICKING MULTIFOCAL VITELLIFORM MACULAR DYSTROPHY: AN OCULAR SIDE EFFECT OF MITOGEN/EXTRACELLULAR SIGNAL-REGULATED KINASE INHIBITORS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20179232" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22767668" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19706763" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24864047" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Transient MEK inhibitor-associated retinopathy in metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23555064" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Bilateral Multifocal Central Serous-Like Chorioretinopathy due to MEK Inhibition for Metastatic Cutaneous Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26951625" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ocular toxicities of MEK inhibitors and other targeted therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF-mutated melanoma patients (pts) treated in the coBRIM study</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36310331" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23434072" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of inhibition of the FGFR-MAPK signaling pathway on the development of ocular toxicities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26123090" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Serous Retinopathy Associated with Mitogen-Activated Protein Kinase Kinase Inhibition (Binimetinib) for Metastatic Cutaneous and Uveal Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28444112" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28709702" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical and Morphologic Characteristics of MEK Inhibitor-Associated Retinopathy: Differences from Central Serous Chorioretinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Reversible Macular Lesions in the Setting of Oral Pan-Fibroblast Growth Factor Inhibitor for the Treatment of Bladder Cancer</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28965185" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203698" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32203698" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29567798" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538953" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16283570" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099440" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534492" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23045571" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087944" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25389947" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25658618" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29121363" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207976" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27090545" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : A rare case of thyroid storm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19018089" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Phase I/II study of ipilimumab for patients with metastatic melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25891173" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pembrolizumab versus Ipilimumab in Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27092830" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590637" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590637" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24590637" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30054605" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29488243" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27649838" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27649838" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34724392" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34724392" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20979469" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25170012" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24573551" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23724913" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24616318" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24616318" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Optic neuropathy and blindness associated with crizotinib for non-small-cell lung cancer with EML4-ALK translocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Visual Disturbances in Patients (PTS) with Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Crizotinib</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16974155" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Clinical and in vivo confocal microscopy findings in patients receiving tamoxifen citrate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22352823" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Tamoxifen keratopathy as seen with in-vivo confocal microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573106" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1385761" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Phase I clinical and pharmacokinetics study of high-dose toremifene in postmenopausal patients with advanced breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/647693" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Tamoxifen retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7674322" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8622006" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Tamoxifen-associated eye disease. A review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17601434" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Peripheral retinopathy and maculopathy in high-dose tamoxifen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9559735" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Long-term tamoxifen citrate use and potential ocular toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7225310" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Tamoxifen retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1591689" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. A prospective study of 63 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11239879" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Tamoxifen retinopathy in a male patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9373465" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Retinal changes associated with tamoxifen treatment for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19248974" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Ocular side effects associated with imatinib mesylate and perifosine for gastrointestinal stromal tumor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181401" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12964961" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Ocular side-effects associated with imatinib mesylate (Gleevec).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12209733" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Severe periorbital edema secondary to STI571 (Gleevec).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14739914" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Periorbital oedema and epiphora as ocular side effects of imatinib mesylate (Gleevec).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18192104" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Conjunctival hemorrhagic events associated with imatinib mesylate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18061664" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Ocular side effects in chronic myeloid leukemia patients treated with imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12614767" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Resolution of leukemic retinopathy following treatment with imatinib mesylate for chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22493373" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Retinal neovascularization and hemorrhage associated with the use of imatinib (Gleevec(®)) in a patient being treated for gastrointestinal stromal tumor (GIST).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22960614" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Imatinib mesylate (Gleevec) induced unilateral optic disc edema.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17562067" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Bilateral cystoid macular edema in a patient with chronic myeloid leukaemia under treatment with imanitib mesylate: report of an unusual side effect.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15085156" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Visual disturbance due to retinal edema as a complication of imatinib.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18773274" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Optic disc edema as a possible complication of Imatinib mesylate (Gleevec).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16473243" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Imatinib as a cause of cystoid macular edema following uneventful phacoemulsification surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17410337" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Imatinib-induced optic neuritis in a patient of chronic myeloid leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19512898" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22068222" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25238138" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Rapid clinical improvement of peripheral artery occlusive disease symptoms after nilotinib discontinuation despite persisting vascular occlusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31229240" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33719653" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Ibrutinib-related uveitis: A report of two severe cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539715" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539715" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36097868" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Corneal toxicity with belantamab mafodotin: Multi-institutional real-life experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356140" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356140" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31356140" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24974380" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Chalazia associated with bortezomib therapy for multiple myeloma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26469392" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Association Between Bortezomib Therapy and Eyelid Chalazia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26330998" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Chalazia Development in Multiple Myeloma: A New Complication Associated with Bortezomib Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27349766" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Treatment With Doxycycline for Severe Bortezomib-Associated Blepharitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10715290" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Docetaxel administered on a weekly basis for metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23650421" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15319242" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470213" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12045065" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23650413" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Epiphora and canalicular stenosis associated with adjuvant docetaxel in early breast cancer: is excessive tearing clinically important?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12879466" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11735790" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16132528" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Electrophysiological evaluation of visual pathways in paclitaxel-treated patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7913722" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Photopsia during 3-hour paclitaxel administration at doses&gt;or = 250 mg/m2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7912737" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Optic nerve disturbances: a new form of paclitaxel neurotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402182" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Ophthalmic toxicity following paclitaxel infusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24564293" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22023333" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Angiographically silent cystoid macular oedema secondary to paclitaxel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17502517" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Paclitaxel maculopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20805460" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Cystoid macular edema secondary to nab-paclitaxel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12692483" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Cystic maculopathy with normal capillary permeability secondary to docetaxel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17763235" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19001234" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Cystoid macular edema secondary to albumin-bound paclitaxel therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12918558" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4740487" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Excessive lacrimation from fluorouracil treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9513767" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Epiphora in patients receiving systemic 5-fluorouracil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24376315" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7469866" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Punctal-canalicular stenosis related to systemic fluorouracil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3688719" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Ankyloblepharon associated with systemic 5-fluorouracil treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10726804" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4027942" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Surgical treatment of punctal-canalicular fibrosis from 5-fluorouracil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/840160" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Cicatricial ectropion secondary to 5-fluorouracil therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549238" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/646255" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1246307" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Combination chemotherapy as an adjuvant treatment in operable breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055658" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Total body irradiation plus cyclophosphamide versus busulphan with cyclophosphamide as conditioning regimen for patients with leukemia undergoing allogeneic stem cell transplantation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25284463" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Incidence and risk factors for cataract after haematopoietic stem cell transplantation for childhood leukaemia: an LEA study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11952491" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Cataract in children after bone marrow transplantation: relation to conditioning regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332655" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Cytosine-arabinoside-induced keratopathy: a model of corneal proliferation kinetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18500372" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Reduced efficacy of topical corticosteroid in preventing cytarabine-induced kerato-conjunctivitis in patients receiving high-dose cytarabine and total body irradiation for allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6223674" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : High-dose cytosine arabinoside therapy for refractory leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23064892" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Cytarabine toxicity of the corneal endothelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24096522" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Corneal microcysts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3314526" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19799589" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Severe anterior uveitis as a complication of high-dose cytosine-arabinoside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15224375" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Anterior uveitis as a complication of treatment with high dose cytosine-arabinoside.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2097009" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Ophthalmological and other toxicities related to cytosine arabinoside and total body irradiation as preparative regimen for bone marrow transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7973121" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Occlusive microvascular retinopathy with optic disc and retinal neovascularization in acute lymphocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20224467" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Rapid vision loss associated with fludarabine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6608139" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Effectiveness of pentostatin (2'-deoxycoformycin) in refractory lymphoid neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6600401" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : An investigation of 2'-deoxycoformycin in the treatment of cutaneous T-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1988572" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Pentostatin induces durable remissions in hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2783731" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Pentostatin in the treatment of advanced hairy cell leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2993534" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Low-dose deoxycoformycin in lymphoid malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3263563" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Deoxycoformycin treatment for childhood T-cell acute lymphoblastic leukemia early in second remission: a Pediatric Oncology Group Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10877045" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Pentostatin (Nipent): a review of potential toxicity and its management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7296473" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427239" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Methotrexate-induced optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15937433" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Reversible optic neuropathy associated with low-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1568425" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Visual field defects during low-dose methotrexate therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190135" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Visual field changes in methotrexate therapy. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14963199" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21187510" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Pemetrexed-induced eyelid edema: incidence and clinical manifestations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16996165" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Pemetrexed-induced edema of the eyelid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21892100" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Skin toxicities compromise prolonged pemetrexed treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20488577" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : Pemetrexed-induced edema of the eyelid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2596552" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Ocular adverse reactions associated with adriamycin (doxorubicin).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17305726" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Ocular presentations of breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11299845" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9255269" id="rid220" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>221 : High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21193421" id="rid221" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>222 : Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17159192" id="rid222" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>223 : Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18687447" id="rid223" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>224 : Acute promyelocytic leukemic involvement of the optic nerves following mitoxantrone treatment for multiple sclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20177954" id="rid224" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>225 : Vogt-Koyanagi-Harada disease occurring during interferon-alpha and ribavirin therapy for chronic hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21494079" id="rid225" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>226 : Vogt-Koyanagi-Harada disease occurring during pegylated interferon-α2b and ribavirin combination therapy for chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633182" id="rid226" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>227 : Vogt-Koyanagi-Harada disease associated with interferon alpha-2b/ribavirin combination therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16310490" id="rid227" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>228 : Vogt-Koyanagi-Harada disease in patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3492259" id="rid228" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>229 : Interferon therapy of non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11943258" id="rid229" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>230 : Trichomegaly following treatment with interferon alpha-2b.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16336462" id="rid230" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>231 : Pegylated interferon-induced eyelid and eyebrow trichomegaly during chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926205" id="rid231" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>232 : An unusual adverse effect of interferon: hypertrichosis of the eyelashes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7666100" id="rid232" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>233 : Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2315793" id="rid233" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>234 : Hypertrichosis of the eyelashes associated with interferon-alpha therapy for chronic granulocytic leukemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10450390" id="rid234" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>235 : Ocular complications with high-dose interferon alpha in chronic active hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11320013" id="rid235" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>236 : Interferon-induced retinopathy in asymptomatic cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8447745" id="rid236" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>237 : Interferon-associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11384576" id="rid237" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>238 : Retinopathy associated with high-dose interferon alfa-2b therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12543766" id="rid238" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>239 : Severe interferon associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15548803" id="rid239" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>240 : Is screening for interferon retinopathy in hepatitis C justified?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9602634" id="rid240" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>241 : Interferon associated retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11567959" id="rid241" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>242 : Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19940529" id="rid242" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>243 : Pegylated-interferon-associated retinopathy in chronic hepatitis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962387" id="rid243" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>244 : A prospective study of change in visual function in patients treated with pegylated interferon alpha for hepatitis C in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12441848" id="rid244" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>245 : Ocular manifestations of hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20020238" id="rid245" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>246 : Retinopathy in hepatitis C patients due to combination therapy with pegylated interferon and ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16329072" id="rid246" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>247 : Branch retinal artery occlusion combined with branch retinal vein occlusion in a patient with hepatitis C treated with interferon and ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11584864" id="rid247" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>248 : Presumed interferon-associated bilateral macular arterial branch obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17197556" id="rid248" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>249 : Retinal circulatory changes associated with interferon-induced retinopathy in patients with hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15771758" id="rid249" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>250 : Retinal toxicity during pegylated alpha-interferon therapy for chronic hepatitis C: a multifocal electroretinogram investigation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23113644" id="rid250" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>251 : Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7836721" id="rid251" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>252 : Optic tract neuropathy complicating low-dose interferon treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516525" id="rid252" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>253 : Natural interferon therapy: optic nerve ischemic damage?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639655" id="rid253" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>254 : Anterior ischemic optic neuropathy secondary to interferon alfa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19227928" id="rid254" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>255 : [Serious loss of vision in bilateral anterior ischemic optic neuropathy caused by interferon].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10218534" id="rid255" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>256 : Severe loss of vision during adjuvant interferon alfa-2b treatment for malignant melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7661198" id="rid256" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>257 : Interferon may cause retinopathy during hepatitis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17589934" id="rid257" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>258 : Intraocular complications of IFN-alpha and ribavirin therapy in patients with chronic viral hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19585362" id="rid258" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>259 : Anterior ischemic optic neuropathy associated with pegylated interferon therapy for chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17318204" id="rid259" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>260 : Bilateral non-arteritic ischemic optic neuropathy associated with pegylated interferon for chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9581701" id="rid260" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>261 : Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20351572" id="rid261" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>262 : Pegylated interferon alpha-associated optic neuropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28281024" id="rid262" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>263 : Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25114574" id="rid263" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>264 : Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32892426" id="rid264" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>265 : Paclitaxel- and/or cyclophosphamide-induced severe ischaemic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31874711" id="rid265" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>266 : Carboplatin- and/or paclitaxel-induced ischemic retinopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11020424" id="rid266" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>267 : Bilateral blindness and lumbosacral myelopathy associated with high-dose carmustine and cisplatin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6331626" id="rid267" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>268 : Intracarotid infusion of cis-diamminedichloroplatinum in the treatment of recurrent malignant brain tumors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9078334" id="rid268" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>269 : Retinal toxicity associated with cisplatin and etoposide in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1558119" id="rid269" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>270 : Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8119103" id="rid270" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>271 : Negative-type electroretinogram from cisplatin toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2986069" id="rid271" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>272 : Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24575012" id="rid272" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>273 : Unilateral Optic Disc Papilloedema following Administration of Carboplatin Chemotherapy for Ovarian Carcinoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8518227" id="rid273" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>274 : Ophthalmic toxicity during carboplatin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25198406" id="rid274" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>275 : Idiopathic intracranial hypertension and oxaliplatin: a causal association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7138345" id="rid275" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>276 : Ocular toxicity associated with high-dose carmustine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8628565" id="rid276" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>277 : Retinopathy and optic neuropathy in bone marrow transplantation for breast cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10516683" id="rid277" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>278 : Optic disc and retinal microvasculopathy after high-dose chemotherapy and autologous hematopoietic progenitor cell support.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5034421" id="rid278" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>279 : Treatment of adrenocortical carcinoma with o,p'-DDD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5923599" id="rid279" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>280 : Adrenal cortical carcinoma. Results of treatment with o,p'DDD in 138 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8156857" id="rid280" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>281 : Terson's syndrome in a patient with acute promyelocytic leukemia on all-trans retinoic acid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14730300" id="rid281" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>282 : Intracranial hypertension secondary to all-trans retinoic acid treatment for leukemia: diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2525470" id="rid282" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>283 : Tolerability of the synthetic retinoid Fenretinide (HPR).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18523815" id="rid283" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>284 : Total rod ERG suppression with high dose compassionate Fenretinide usage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2148744" id="rid284" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>285 : Phase II study of fenretinide (N-[4-hydroxyphenyl]retinamide) in advanced breast cancer and melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2713307" id="rid285" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>286 : Visual toxicity of synthetic retinoids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2937817" id="rid286" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>287 : Abnormal night vision and altered dark adaptometry in patients treated with isotretinoin for acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2940999" id="rid287" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>288 : Abnormal retinal function associated with isotretinoin therapy for acne.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4294312" id="rid288" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>289 : Ocular complications of vincristine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19770526" id="rid289" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>290 : Simultaneous isolated bilateral facial palsy: a rare vincristine-associated toxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14970804" id="rid290" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>291 : Isolated abducens nerve palsy induced by vincristine therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/287774" id="rid291" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>292 : Unilateral optic neuropathy following vincristine chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1251878" id="rid292" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>293 : Optic neuropathy presumably caused by vincristine therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
